# EDGAR Filing Document

**Accession Number:** 0002038185
**File Stem:** 0001213900-25-093470
**Filing Date:** 2025-9
**Character Count:** 297717
**Document Hash:** 8113f236be1a08d88860cbea93fa1e23
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-093470.hdr.sgml**: 20250930

**ACCESSION NUMBER**: 0001213900-25-093470

**CONFORMED SUBMISSION TYPE**: 1-SA

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250930

**DATE AS OF CHANGE**: 20250930

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jabez Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0002038185
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 993344534
- **STATE OF INCORPORATION:** FL

**FILING VALUES:**
- **FORM TYPE:** 1-SA
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 24R-00990
- **FILM NUMBER:** 251358409

**BUSINESS ADDRESS:**
- **STREET 1:** 6393 BLACKSTONE DR.
- **CITY:** ZIONSVILLE
- **STATE:** IN
- **ZIP:** 46077
- **BUSINESS PHONE:** 888-645-3947

**MAIL ADDRESS:**
- **STREET 1:** 6393 BLACKSTONE DR.
- **CITY:** ZIONSVILLE
- **STATE:** IN
- **ZIP:** 46077

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 1-SA**

 **☒ SEMIANNUAL REPORT PURSUANT TO REGULATION A**

**or**

**SPECIAL FINANCIAL REPORT PURSUANT TO REGULATION A**

For the fiscal semiannual period ended June 30, 2025

Jabez Biosciences, Inc.

(Exact name of issuer as specified in its charter)

<u>Florida</u> <u>99-3344534</u> <br> State or other jurisdiction of <br> incorporation or organization (I.R.S. Employer <br> Identification Number)

**<u>2009 Mackenzie Way, Suite 100, Cranberry Twp., PA 16066</u>**

(Address, including zip code of principal executive offices)

**<u>888-645-3947</u>**

(Issuer's telephone number, including area code)

**Item 1. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The information and financial data discussed below is derived from our unaudited financial statements, herein, for the period from January 1, 2025 to June 30, 2025. The unaudited financial statements were prepared and presented in accordance with generally accepted accounting principles in the United States. The information and financial data discussed below is only a summary and should be read in conjunction with the related notes contained elsewhere in this filing. The financial statements contained elsewhere in this filing fully represent our financial condition and operations; however, they are not indicative of our future performance.*

**Results of Operations**

**Results of Operations for the six months ended June 30, 2025 (unaudited)**

**<u>Revenue</u>**: Management does not expect the Company to generate any significant , including product sales, for at least the next two years, if ever. The Company's oncology product candidates remain in clinical development, and any revenues in upcoming periods are expected to be derived primarily from potential collaborations, licensing arrangements, or other strategic transactions rather than from commercial sales.

**<u>Research and development expense</u>**: The Company incurred $638,010 in research and development expenses during the six months ended June 30, 2025. These expenses were primarily associated with initiating the Company's phase 1 clinical trial, including costs related to clinical trial material manufacturing, development of the clinical data management software platform, patent expenses, and other preparatory activities necessary to support the trial's launch.

**<u>Other operating expenses</u>**: The Company incurred $711,194 in other operating expenses, including salaries and wages, professional services, and general and administrative expenses during the six months ended June 30, 2025.

**<u>Net loss:</u>** Net loss for the six months ended June 30, 2025, was $1,522,383.

The table below sets forth line items from the Company's unaudited Statement of Operations for the period from January 1, 2025 to June 30, 2025.

---

| | |
|:---|:---|
| Revenue: |  |
| &nbsp;&nbsp;&nbsp;Sales | $- |
| Total revenue |  |
| Expenses: |  |
| &nbsp;&nbsp;&nbsp;Research and development expense | 638010 |
| &nbsp;&nbsp;&nbsp;Interest expense | 174273 |
| &nbsp;&nbsp;&nbsp;Salaries and wages expense | 282462 |
| &nbsp;&nbsp;&nbsp;Professional services expense | 413999 |
| &nbsp;&nbsp;&nbsp;General and administrative expenses | 14733 |
| &nbsp;&nbsp;&nbsp;Other expense | (1094) |
| Net loss before income taxes | (1522383) |
| Provision for income taxes | - |
| Net loss | $(1522383) |
| Earnings per share - basic | $(0.04) |
| Earnings per share - diluted | $(0.04) |
| Weighted average shares outstanding - basic and diluted | 36928974 |

---

**Liquidity and Capital Resources** 

As of June 30, 2025, we had cash of $176,963. During the six months ended June 30, 2025, we used approximately $997,144 in cash for operating activities and were provided $850,100 through financing activities.

In fiscal year 2024, the Company entered into an unsecured note agreement with certain shareholders in the aggregate principal amount of $1,000,000. These notes bear interest at 10% per annum and a maturity date of October 15, 2024. Upon the occurrence and during the continuance of any default by the Company under these notes, which default is not cured within fifteen (15) days following written notice of such default from the payee, the payee may declare the entire unpaid principal and unpaid interest immediately due and payable. As of October 1, 2024, the above referenced notes were extended by mutual agreement of the Company and the note holders for an additional 90-day period and became due and payable on January 15, 2025. Both notes were paid in full on January 12, 2025.

In fiscal year 2024, the Company entered into an unsecured note agreement with an unrelated party in the principal amount of $250,000. The note bears interest of 50,000 and matures on March 16, 2026 . Interest and principal on the note is paid in an amount equal to fifty (50) percent of net proceeds, less expenses, from the sale of the Company's Regulation A filing. All unpaid principal and interest is paid at maturity. Upon the occurrence and during the continuance of any default by the Company under these notes, which default is not cured within fifteen (15) days following written notice of such default from the payee, the payee may declare the entire unpaid principal and unpaid interest immediately due and payable. As additional consideration for the note, the Company agreed to issue 250,000 shares of our common stock to the note holder.

In fiscal year 2024, the Company entered into an unsecured note agreement with an unrelated party in the principal amount of $250,000. These note bears interest of at 6% per annum and with a maturity date on May 11, 2025. Upon the occurrence and during the continuance of any default by the Company under the note, which default is not cured within fifteen (15) days following written notice of such default from the payee, the payee may declare the entire unpaid principal and unpaid interest immediately due and payable. As additional consideration for the note, the Company agreed to issue 250,000 shares of our common stock to the note holder. On May 29, 2025, parties agreed to convert the principal of the note into 1,000,000 shares of common stock, accompanied with a put option that entitles the holder to require the company to repurchase 250,000 shares at a price of $300,000 on the 6-month anniversary of execution of the agreement. The repurchase option requires a thirty-day prior written notice of intent to exercise.

In April 2025, the Company entered into an unsecured note agreement with an unrelated party in the principal amount of $200,000 together with interest of 18% and with a maturity date of June 29, 2025. On June 29, 2025, accrued interest in the amount of $6,016 was paid in full, and the principal amount of the note was extended to a maturity date of August 29, 2025. All other terms and conditions of the note remained unchanged. As of June 30, 2025, the outstanding principal balance was $200,000 with accrued interest of $99. On August 29, 2025, accrued interest in the amount of $6,016 was paid in full and the principal amount of the note was extended to a maturity date of October 29, 2025. All other terms and conditions of the note remained unchanged.

During the six months ended June 30, 2025, the Company entered into subscription agreements with a third party to issue shares of its common stock. One of the Company's non-officer directors is a member of the third party entity. Pursuant to these agreements, the Company issued 650,000 shares of common stock for total cash proceeds of $650,000, all of which was received during the six-month period ended June 30, 2025.

We believe the capital raised to date and through our existing offerings, combined with our cash on hand, will be sufficient to meet all financial needs and obligations for the next twelve months. However, our liquidity needs are affected by changes in business operations, including investments in product development.

The accompanying financial statements have been prepared in conformity with GAAP, which contemplate the continuation of the Company as a going concern, which is dependent upon the Company's ability to obtain sufficient financing or establish itself as a profitable business. As of June 30, 2025, the Company had an accumulated deficit of $2,651,373 and net loss of $1,522,383. These conditions raise substantial doubt about the Company's ability to continue as a going concern for at least one year from the date the financial statements are issued.

The Company's continuation as a going concern is dependent upon its ability to obtain additional financing, generate revenues, and ultimately achieve profitable operations. We may also seek additional capital resources through public or private debt or equity offerings to support future growth opportunities or other corporate purposes. However, there can be no assurance that additional financing will be available on favorable terms, or at all.

Our liquidity may be impacted by a number of risks and uncertainties, including:

● Economic Conditions: A downturn in the economy could negatively affect our ability to raise capital.

● Credit Market Volatility: If the credit markets remain restrictive, our ability to obtain financing on favorable terms may be limited.

● Operational Risks: Any disruptions in our operations, including supply chain issues or regulatory changes, could impact our ability to raise capital.

Our management's discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in the notes to our financial statements appearing elsewhere in this Offering Document, we believe that the accounting policies discussed above are critical to our financial results and to the understanding of our past and future performance, as these policies relate to the more significant areas involving management's estimates and assumptions. We consider an accounting estimate to be critical if: (1) it requires us to make assumptions because information was not available at the time or it included matters that were highly uncertain at the time we were making our estimate; and (2) changes in the estimate could have a material impact on our financial condition or results of operations.

**<u>Cash Flows</u>**

***Cash Flow used in Operating Activities***

For the six months ended June 30, 2025, the Company used $997,144 in operating activities. The cash used in operations was primarily attributable to research and development expenses related to the initiation of the Company's phase 1 clinical trial, general and administrative costs, and personnel-related expenses. As a pre-revenue development-stage company, we expect to continue incurring negative cash flows from operations in the near term as we advance our clinical and regulatory program.

 ****

***Cash Flows from Financing Activities***

The Company generated $850,100 in net cash from financing activities during the six months ended June 30, 2025. This amount primarily reflects proceeds from the issuance of common stock and promissory notes, which were used to fund operating and development activities. The Company made debt repayments of $800,000 during the period.

**Material Cash Commitments.** The Company's material future cash commitments, to be paid from cash flows from operations, are to repay its current debt obligations and obligations in connection with the OSIF License Agreement. The Company does not have any material commitments for capital expenditures. The following table shows the material future commitments for the years ending December 31:

---

| | |
|:---|:---|
| 2025 | $1113000 |
| 2026 | 301648 |
| 2027 | 100000 |
| Total | $1514648 |

---

**Off-Balance Sheet Arrangements**

We do not have any off-balance sheet arrangements or relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities.

**Item 2. Other Information** 

None.

**Item 3. Financial Statements**

**JABEZ BIOSCIENCES, INC.**

**BALANCE SHEET**

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **June 30,<br> 2025<br> (unaudited)** | **December 31,<br> 2024** |
| **ASSETS** | | |
| **CURRENT ASSETS** | | |
| &nbsp;&nbsp;&nbsp;Cash | $176963 | $324007 |
| &nbsp;&nbsp;&nbsp;Prepaid assets | 127098 | 3041 |
| &nbsp;&nbsp;&nbsp;Deferred offering costs | 64248 | 64248 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL CURRENT ASSETS | 368309 | 391296 |
| **OTHER ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Intangible assets, net | 563465 | 675000 |
| &nbsp;&nbsp;&nbsp;Total other assets | 563465 | 675000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL ASSETS | $931774 | $1066296 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)** |  |  |
| **CURRENT LIABILITIES** |  |  |
| &nbsp;&nbsp;&nbsp;Notes payable, current, net of debt discount of $71,267 and $90,450 | $378734 | $959550 |
| &nbsp;&nbsp;&nbsp;Accounts payable | 343942 | 275565 |
| &nbsp;&nbsp;&nbsp;Accrued interest payable, current | 21637 | 38000 |
| &nbsp;&nbsp;&nbsp;Accrued expenses | 30462 | 11622 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL CURRENT LIABILITIES | 774775 | 1284737 |
| **LONG TERM LIABILITIES** |  |  |
| &nbsp;&nbsp;&nbsp;Note payable, long term, net of debt discount of $0 and $121,071 |  | 128929 |
| &nbsp;&nbsp;&nbsp;Accrued interest payable, long term | - | 1649 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL LONG TERM LIABILITIES | - | 130578 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL LIABILITIES | 774775 | 1415315 |
| **STOCKHOLDERS' EQUITY (DEFICIT)** |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock, $0.00 par value, 10,000,000 shares authorized, 0 issued and outstanding at June 30, 2025 and December 31, 2024 |  |  |
| &nbsp;&nbsp;&nbsp;Common stock, $0.00 par value, 100,000,000 shares authorized, 38,177,968 and 36,149,667 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively | 2808382 | 1580071 |
| &nbsp;&nbsp;&nbsp;Subscription receivable | (10) | (800100) |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (2651373) | (1128990) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL STOCKHOLDERS' EQUITY (DEFICIT) | 156999 | (349019) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $931774 | $1066296 |

---

*The accompanying notes are an integral part of the financial statements.*

**JABEZ BIOSCIENCES, INC.**

**STATEMENT OF OPERATIONS**

---

| | | |
|:---|:---|:---|
|  | **Six Months<br> Ended <br> June 30,<br> 2025 (unaudited)** | **For the<br> Period<br> From<br> Inception<br> (May 22,<br> 2024) to<br> June 30,<br> 2024** |
| **REVENUE** | | |
| Sales | $- | $- |
| Cost of goods | - | - |
| Gross profit | - | - |
| **OPERATING EXPENSES** |  |  |
| Research and development expense | 638010 |  |
| Salaries and wages expense | 282462 |  |
| Professional services expense | 413999 | 12500 |
| General and administrative expenses | 14733 | - |
| Total operating expenses | 1349204 | 12500 |
| LOSS FROM OPERATIONS | (1349204) | (12500) |
| **OTHER INCOME (EXPENSE)** |  |  |
| Interest expense | (174273) | (113) |
| Other (expense) income, net | 1094 | - |
| TOTAL OTHER INCOME (EXPENSE), net | (173179) | (113) |
| LOSS BEFORE INCOME TAXES | (1522383) | (12613) |
| **PROVISION FOR INCOME TAXES** |  |  |
| NET LOSS | $(1522383) | $(12613) |
| **LOSS PER SHARE** |  |  |
| Loss per share, basic and fully diluted | $(0.04) | $(0.00) |
| Weighted average number of common shares outstanding | 36928974 | 14566113 |

---

*The accompanying notes are an integral part of the financial statements.*

**JABEZ BIOSCIENCES, INC.**

**STATEMENT OF STOCKHOLDERS' EQUITY**

**(unaudited)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **COMMON STOCK** | **COMMON STOCK** | | | |
|  | **SHARES** | **AMOUNT** | **SUBSCRIPTION**<br>**RECEIVABLE** | **ACCUMULATED**<br>**DEFICIT** | **TOTAL**<br>**EQUITY** |
| BALANCE AT MAY 22, 2024 |  | $- | $- | $- | $- |
| &nbsp;&nbsp;&nbsp;Shares issued for cash | 17115500 | 2000 |  |  | 2000 |
| &nbsp;&nbsp;&nbsp;Shares subscribed | 13550000 | 1300 | (1300) |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | - | - | - | (12613) | (12613) |
| BALANCE AT JUNE 30, 2024 | 30665500 | $3300 | $(1300) | $(12613) | $(10613) |
| BALANCE AT DECEMBER 31, 2024 | 36149667 | $1580071 | $(800100) | $(1128990) | $(349019) |
| &nbsp;&nbsp;&nbsp;Shares issued for cash | 650000 | 650000 | 800100 |  | 1450100 |
| &nbsp;&nbsp;&nbsp;Shares subscribed | 50000 | 10 | (10) |  |  |
| &nbsp;&nbsp;&nbsp;Shares issued for services | 300000 | 300000 |  |  | 300000 |
| &nbsp;&nbsp;&nbsp;Shares issued for conversion of debt | 1028301 | 278301 |  |  | 278301 |
| &nbsp;&nbsp;&nbsp;Net loss | - | - | - | (1522383) | (1522383) |
| BALANCE AT JUNE 30, 2025 | 38177968 | $2808382 | $(10) | $(2651373) | $156999 |

---

*The accompanying notes are an integral part of the financial statements.*

**JABEZ BIOSCIENCES, INC.**

**STATEMENT OF CASH FLOWS**

---

| | | |
|:---|:---|:---|
|  | **Six Months <br> Ended <br> June 30,<br> 2025<br> (unaudited)** | **For the <br> Period<br> from<br> Inception<br> (May 22,<br> 2024) to<br> June 30,<br> 2024** |
| **OPERATING ACTIVITIES** | | |
| &nbsp;&nbsp;&nbsp;Net loss | $(1522383) | $(12613) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | 111535 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of shares issued for prepaid assets | 123975 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued interest payable | 10289 | 113 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt discount | 140254 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares issued for non-employee services | 50000 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Increase) decrease in: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid assets | 1969 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 68377 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 18840 | - |
| NET CASH USED IN OPERATING ACTIVITIES | (997144) | (12500) |
| **INVESTING ACTIVITIES** |  |  |
| NET CASH USED IN INVESTING ACTIVITIES |  |  |
| **FINANCING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from notes payable | 200000 | 22500 |
| &nbsp;&nbsp;&nbsp;Repayment of notes payable | (800000) |  |
| &nbsp;&nbsp;&nbsp;Shares issued for cash | 1450100 | 2000 |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 850100 | 24500 |
| NET INCREASE (DECREASE) IN CASH | (147044) | 12000 |
| CASH AT BEGINNING OF PERIOD | 324007 | - |
| CASH AT END OF PERIOD | $176963 | $12000 |
| **SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION** |  |  |
| &nbsp;&nbsp;&nbsp;Interest paid | $23729 | $- |
| &nbsp;&nbsp;&nbsp;Taxes paid | $- | $- |
| **NON-CASH INVESTING AND FINANCING INFORMATION** |  |  |
| &nbsp;&nbsp;&nbsp;Shares issued in exchange for subscriptions receivable | $10 | $1300 |
| &nbsp;&nbsp;&nbsp;Shares issued in exchange for conversion of debt | $278301 | $- |
| &nbsp;&nbsp;&nbsp;Shares issued in exchange for prepaid assets | $250000 | $- |

---

*The accompanying notes are an integral part of the financial statements.*

**JABEZ BIOSCIENCES, INC.**

**NOTES TO FINANCIAL STATEMENTS**

**June 30, 2025**

**NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION**

**Nature of Business**

Jabez Biosciences, Inc. ("Jabez", the "Company") was incorporated in the state of Florida on May 22, 2024. The Company is a biotechnology company developing liquid and solid tumor therapies. The current business model is designed around furthering the development of its current product portfolio in new and exciting therapeutic areas such as oncology.

**Basis of Presentation** – The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). In the opinion of management, the accompanying financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company's financial position, results of operations, and cash flows.

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Cash** – For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents. At times, balances of cash and cash equivalents at financial banking institutions exceeded the federally insured limit of $250,000. The Company regularly monitors the financial condition of the institution in which it has depository accounts and believes the risk of loss is minimal.

**Income Taxes –** The Company accounts for income taxes in accordance with Accounting Standards Codification ("ASC") 740, *Income Taxes*. Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes related primarily to temporary differences between reporting of income and expenses for financial reporting purposes and income tax purposes. The deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes also are recognized for operating losses that are available to offset future federal income taxes.

ASC 740 clarifies the accounting and reporting for uncertainties in income tax law within subtopic ASC 740-10-25-5. The guidance prescribes a comprehensive model for the financial statement recognition, measurement, presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. Management believes that there is no liability related to uncertain tax positions as of June 30, 2025.

**Use of Estimates –** The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**Recent Accounting Pronouncements** – During the six months ended June 30, 2025, there were new accounting pronouncements issued by the Financial Accounting Standards Board ("FASB"). Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company's financial statements.

**Going Concern Risk –** The accompanying financial statements have been prepared in conformity with GAAP, which contemplate the continuation of the Company as a going concern, which is dependent upon the Company's ability to obtain sufficient financing or establish itself as a profitable business. As of June 30, 2025, the Company had an accumulated deficit of $2,651,372, and for the six months ended June 30, 2025, the Company had a net loss of $1,522,383. These conditions raise substantial doubt about the Company's ability to continue as a going concern for at least one year from the date the financial statements are issued.

The Company's continuation as a going concern is dependent upon its ability to obtain additional financing, generate revenues, and ultimately achieve profitable operations. Management is actively pursuing funding opportunities and has demonstrated the ability to raise capital, as discussed in Note 10, Subsequent Events. However, there can be no assurance that management will be successful in obtaining additional funding or in attaining profitable operations.

**Fair Value of Financial Instruments** – The Company calculates the fair value of its assets and liabilities which qualify as financial instruments and includes this additional information in the notes to financial statements when the fair value is different than the carrying value of those financial instruments. The methods and assumptions applied in determining the fair value of each class of financial assets and financial liabilities of the Company are disclosed in the respective accounting policies. The estimated fair value of cash and subscriptions receivable approximate their carrying amounts due to the short-term nature of these instruments. For debt instruments issued at a discount, the carrying amount is initially recorded net of the unamortized discount, which is amortized to interest expense over the term of the debt using the effective interest method. When measuring fair value, the Company considers the impact of the discount, along with other relevant inputs such as market interest rates, credit spreads, and the terms of the instrument.

**Earnings Per Share** – Basic earnings per share (or loss per share), is computed by dividing the earnings (loss) for the period by the weighted average number of common stock shares outstanding for the period. Diluted earnings per share reflects potential dilution of securities by including other potentially issuable shares of common stock, including shares issuable upon conversion of convertible securities or exercise of outstanding stock options and warrants, in the weighted average number of common shares outstanding for the period. Therefore, because including shares issuable upon conversion of convertible securities and/or exercise of outstanding options and warrants would have an anti-dilutive effect on the loss per share, only the basic earnings (loss) per share is reported in the accompanying financial statements. The Company does not have other potentially issuable shares of stock.

**Segment Reporting** – Operating segments are components of an enterprise about which separate financial information is available and is evaluated regularly by management, namely the Chief Operating Decision Maker ("CODM") of an organization, in order to determine operating and resource allocation decisions. By this definition, the Company has identified its Chief Executive Officer as the CODM. The Company is operating in one segment, Biotechnology. This segment is non-revenue generating and incurs expenses by developing its biotechnology product pipeline.

**Research and Development** – Research and development costs are expensed when incurred. During the six months ended June 30, 2025, research and development expenses totaled $638,010.

**Intangible Assets** - The Company recorded the upfront license fee and the probable and estimable maintenance fees as a finite-lived intangible asset in accordance with ASC 350-30, *Intangibles – Goodwill and Other: General Intangibles Other Than Goodwill*. The estimable maintenance fees are amortized on a straight-line basis over the period until they become due, and the license agreement is amortized on a straight-line basis over its estimated useful life of 15 years. The asset had a gross carrying amount of $675,000 as of January 1, 2025, and a net carrying amount of $563,465 as of June 30, 2025, reflecting amortization expense of $111,535 for the six months ended June 30, 2025. The asset is reviewed for impairment whenever events or changes in circumstances indicate that its carrying amount may not be recoverable.

**Deferred Offering Costs** – Deferred offering costs, consisting primarily of legal, accounting, and other fees directly related to the Company's planned equity or debt offerings, are capitalized on the balance sheet. These costs are deferred until the completion of the related offering, at which time they are reclassified to equity (as a reduction of additional paid-in capital) or to debt (as a reduction of the carrying amount of the debt), depending on the nature of the offering. If the offering is abandoned, such costs are expensed immediately in the period in which the offering is terminated. At June 30, 2025, the Company recorded $64,248 of deferred offering costs.

**NOTE 3 – DEBT**

In August 2024, the Company entered into an unsecured note agreement with an unrelated party in the principal amount of $250,000 together with interest of 10%, with a maturity date of October 15, 2024. As of December 31, 2024 the note was in default, and accrued interest on this note was $9,452. This note was paid in full on January 13, 2025, including accrued interest of $10, 274.

In August 2024, the Company entered into an unsecured note agreement with a related party in the principal amount of $750,000 together with interest of 10%, with a maturity date of October 15, 2024. A partial payment of $200,000 on the principal balance of the note was paid in October 2024. As of December 31, 2024 the note was in default, and accrued interest on this note was $26,493. This note was paid in full on January 13, 2025. The accrued interest, in the amount of $28,301, was satisfied with the issuance of 28,301 shares of common stock. See Note 8, Related Party Transactions, for additional information.

In November 2024, the Company entered into a financing agreement with an unrelated party under which it issued a promissory note with a principal amount of $250,000 together with interest of 6%, payable at maturity on May 11, 2025. As part of the financing agreement, the Company also issued 250,000 shares of its common stock. The relative fair value of the common stock was determined to be $124,973, which was recorded as a debt discount and amortized over the term of the note using the effective interest rate method.

On May 29, 2025, the principal of the note was converted into 1,000,000 shares of common stock, accompanied with a put option that entitles the holder to require the company to repurchase 250,000 shares at a price of $300,000 on the 6-month anniversary of execution of the agreement. The repurchase option requires a thirty-day prior written notice of intent to exercise. The accrued interest, in the amount of $7,438, was paid in full on May 30, 2025. As of June 30, 2025, the debt discount had been fully amortized. Amortization expense related to the debt discount for the six months ended June 30, 2025 was $90,450 and is included in interest expense in the accompanying statement of operations.

In December 2024, the Company entered into a financing agreement with an unrelated party under which it issued a promissory note with a principal amount of $250,000 together with interest of 16%, payable at maturity on March 16, 2026. As part of the financing agreement, the Company also issued 250,000 shares of its common stock. The relative fair value of the common stock was determined to be $125,198, which was recorded as a debt discount and will be amortized over the term of the note using the effective interest rate method.

As of June 30, 2025, the unamortized debt discount was $71,267, and the net carrying amount of the debt was $178,733. Amortization expense related to the debt discount for the six months ended June 30, 2025 was $49,804 and is included in interest expense in the accompanying statement of operations. The note had an outstanding principal balance of $250,000 as of June 30, 2025 and accrued interest of $21,538.

In April 2025, the Company entered into an unsecured note agreement with an unrelated party in the principal amount of $200,000 together with interest of 18%, with a maturity date of June 29, 2025. On June 29, 2025, accrued interest in the amount of $6,016 was paid in full, and the principal amount of the note was extended to a maturity date of August 29, 2025. All other terms and conditions of the note remained unchanged. As of June 30, 2025, the outstanding principal balance was $200,000 with accrued interest of $99. On August 29, 2025, accrued interest in the amount of $6,016 was paid in full and the principal amount of the note was extended to a maturity date of October 29, 2025. All other terms and conditions of the note remained unchanged.

As of June 30, 2025, the total principal amount of notes payable outstanding was $450,000. Of this amount, $200,000 is due in the year ending December 31, 2025, and $250,000 is due in the year ending December 31, 2026.

**NOTE 4 – CAPITAL STRUCTURE**

The total number of shares of stock which the corporation shall have authority to issue is 110,000,000 shares, of which 100,000,000 shares with zero par value shall be designated as Common Stock and 10,000,000 shares with zero par value shall be designated as Preferred Stock. As of June 30, 2025, the Company had 38,177,968 shares of its common stock issued and outstanding, and on December 31, 2024, the Company had 36,149,667 shares of its common stock issued and outstanding.

The Preferred Stock authorized by the Company's Articles of Incorporation may be issued in one or more series. There have been no preferred shares designated as of June 30, 2025. The Board of Directors of the Corporation is authorized to determine or alter the rights, preferences, privileges, and restrictions granted or imposed upon any wholly unissued series of Preferred Stock, and within the limitations or restrictions stated in any resolution or resolutions of the Board of Directors originally fixing the number of shares constituting any series, to increase or decrease (but not below the number of shares of any such series then outstanding) the number of shares of any such series subsequent to the issue of shares of that series, to determine the designation and par value of any series and to fix the numbers of shares of any series.

**NOTE 5 – COMMITMENTS AND CONTINGENCIES**

**Legal Matters** – The Company is currently not a defendant in any litigation or threatened litigation that could have a material effect on the Company's financial statements.

**Master Service Agreement** – On December 31, 2024, the Company entered into a one-year agreement that provides access to an AI-powered marketing software and robotic automation capabilities. Consideration for the contract consists of 250,000 shares of the Company's common stock and a monthly fee of $7,500 beginning in April 2025.

**License Agreement with OSIF** – Under a separate licensing agreement with the Ohio State Innovation Foundation ("OSIF"), the Company is obligated to pay maintenance fees according to the following schedule: $25,000 on July 16, 2025; $50,000 on July 16, 2026; and $100,000 on July 16, 2027. Beginning in 2028, annual maintenance fees of $100,000 will continue to be payable on each anniversary of July 16 until the Company achieves its first commercial sale.

**Put Option Agreement –** On May 29, 2025, in connection with the conversion of the Company's $250,000 promissory note into 1,000,000 shares of common stock, the Company granted the holder a put option to require the Company to repurchase 250,000 shares at a price of $300,000 on the 6-month anniversary of execution of the agreement. The repurchase option requires a thirty-day prior written notice of intent to exercise. As of June 30, 2025, no liability has been recorded related to the put option as the repurchase is contingent upon the holder's election to exercise the option, and the Company will continue to evaluate the likelihood of exercise in future periods.

**NOTE 6 – INCOME TAXES**

For the six months ended June 30, 2025 and 2024, respectively, no income tax expense or benefit was recognized. The Company's deferred tax assets are comprised primarily of net operating loss carryforwards. The Company maintains a full valuation allowance on its deferred tax assets since it has not yet achieved sustained profitable operations. As a result, the Company has not recorded any income tax benefit since its inception.

**NOTE 7 – INTANGIBLE ASSETS**

In July 2024, the Company entered into an exclusive license agreement (the "License Agreement") with the Ohio State Innovation Foundation (OSIF), the technology transfer function of The Ohio State University, and Hendrix College, under which the Company obtained exclusive rights to key patent families and related intellectual property associated with a proprietary dihydroorotate dehydrogenase ("DHODH") small molecule inhibitor. The License Agreement grants the Company exclusive rights to use the licensed patents and related intellectual property in connection with the development and commercialization of DHODH. Through note agreements with third parties discussed in Note 3, Debt, the total consideration paid to OSIF was $500,000 for the upfront license fee. The upfront license fee and the probable and estimable maintenance fees were capitalized as finite-lived intangible assets in the amount of $675,000 and are being amortized on a straight-line basis, with the maintenance fees amortized over the period until they become due and the license agreement amortized over its estimated useful life of 15 years. For the six months ended June 30, 2025, amortization expense totaled $111,535, reducing the carrying amount of the assets to $563,465 as of June 30, 2025. Amortization expense is recorded within research and development expenses in the accompanying statement of operations, and the assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

**NOTE 8 – RELATED PARTY TRANSACTION**

In August 2024, the Company entered into an unsecured note agreement with a member of its Board of Directors in the principal amount of $750,000. The note is classified as a related party transaction and bears interest at a rate of 10%, with a maturity date of October 15, 2024. A partial principal payment of $200,000 was paid in October 2024. The note was in default at December 31, 2024 with accrued interest of $26,493. This note was paid in full on January 13, 2025. The accrued interest, in the amount of $28,301, was satisfied with the issuance of 28,301 shares of common stock.

In September 2024, the Company entered into a subscription agreement with a member of its Board of Directors for the purchase of common stock in a private transaction totaling $1,100,000. The Company had a subscription receivable of $800,000 as of December 31, 2024. The transaction was completed in January 2025, at which time the Company issued the corresponding shares.

During the six months ended June 30, 2025, the Company entered into subscription agreements with a third party entity to issue shares of its common stock. One of the Company's non-officer directors is a member of the third party entity. Pursuant to these agreements, the Company issued 650,000 shares of common stock for total cash proceeds of $650,000, all of which was received during the six-month period ended June 30, 2025.

**NOTE 9 – SEGMENT REPORTING**

Operating segments are components of an enterprise about which separate financial information is available and is evaluated regularly by management, namely the CODM of an organization, in order to determine operating and resource allocation decisions. By this definition, the Company has identified its Chief Executive Officer as the CODM. The Company is operating in one segment, Biotechnology.

Biotechnology Segment: This segment is non-revenue generating and incurs expenses by developing its biotechnology product pipeline. The Biotechnology Segment had total assets of $931,775 as of June 30, 2025.

The Company believes that this structure reflects its current operational and financial management, and that it provides the best structure for the Company to focus on growth opportunities while maintaining financial discipline. The factors used to identify the Biotechnology operating segment were the difference in future potential revenue streams and customer base, the reporting structure for operational and performance information within the Company, and management's decision to organize the Company around the future potential revenue generating activities of the segment.

Segment information relating the Company's operating segment for the six months ended June 30, 2025 is as follows:

---

| | | |
|:---|:---|:---|
|  | **Biotechnology Segment** | **Total** |
| Sales | $– | $– |
| Total operating expenses | 1349204 | 1349204 |
| Loss from operations | (1349204) | (1349204) |
| Interest expense | (174273) | (174273) |
| Other (expense) income, net | 1094 | 1094 |
| Net loss | $(1522383) | $(1522383) |

---

**NOTE 10 – SUBSEQUENT EVENTS**

Management has performed a review of all events and transactions occurring after June 30, 2025 through the date the financial statements were available to be issued for items that would require adjustment to or disclosure in the accompanying financial statements, noting no such items or transactions other than the following:

In August 2025, the Company extended the promissory note in the amount of $200,000 to a maturity date of October 29, 2025. Accrued interest in the amount of $6,016 was paid in full as of August 29, 2025.

Since June 30, 2025 and through the completion of these financial statements, the Company entered into stock purchase agreements for the issuance and sale of shares of common stock. The stock issuances were conducted in sales exempt from registration under Rule 701, Regulation D Rule 506(b) and Regulation A. A total of 1,450,000 shares of common stock were issued under Regulation D Rule 506(b), resulting in gross proceeds of $450,500. In the Company's Regulation A offering, a total of 19,000 shares of common stock were issued, resulting in gross proceeds of $38,000. In addition, under Rule 701, the Company issued 600,000 shares of common stock for services rendered.

**Index to Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| 2.1 | [Articles of Incorporation (Incorporated by reference to Exhibit 2.1 to the Company's Offering Statement on Form 1-A (File No. 024-12509) filed on September 21, 2024)](http://www.sec.gov/Archives/edgar/data/2038185/000121390024080792/ea021496801ex2-1_jabez.htm) |
| 2.3 | [Bylaws (Incorporated by reference to Exhibit 2.3 to the Company's Offering Statement on Form 1-A (File No. 024-12509) filed on September 21, 2024)](http://www.sec.gov/Archives/edgar/data/2038185/000121390024080792/ea021496801ex2-3_jabez.htm) |
| 3.1 | [Unsecured Promissory Note in the principal sum of $250,000 of Jabez Biosciences, Inc. as Maker, Dated December 16, 2024 (Incorporated by reference to Exhibit 3.1 to the Company's Annual Report on Form 1-K (File No. 24R-00990) filed on May 06, 2025)](http://www.sec.gov/Archives/edgar/data/2038185/000121390025039855/ea023887001ex3-1_jabez.htm) |
| 3.2 | [Unsecured Promissory Note in the principal sum of $12,500 of Jabez Biosciences, Inc. as Maker, Dated May 31, 2024 (Incorporated by reference to Exhibit 3.2 to the Company's Annual Report on Form 1-K (File No. 24R-00990) filed on May 06, 2025)](http://www.sec.gov/Archives/edgar/data/2038185/000121390025039855/ea023887001ex3-2_jabez.htm) |
| 4.1 | [Form of Subscription Agreement (Incorporated by reference to Exhibit 4.1 to the Company's Offering Statement on Form 1-A/A (File No. 024-12509) filed on October 29, 2024)](http://www.sec.gov/Archives/edgar/data/2038185/000121390024091806/ea0218868ex4-1_jabez.htm) |
| 6.1 | [Ohio State Innovation Foundation License Agreement (redacted) (Incorporated by reference to Exhibit 6.1 to the Company's Offering Statement on Form 1-A/A (File No. 024-12509) filed on October 29, 2024)](http://www.sec.gov/Archives/edgar/data/2038185/000121390024091806/ea0218868ex6-1_jabez.htm) |
| 6.2 | [Unsecured Promissory Note in the principal sum of $750,000 of Jabez Biosciences, Inc. as Maker, Dated August 14, 2024 (Incorporated by reference to Exhibit 6.2 to the Company's Annual Report on Form 1-K (File No. 24R-00990) filed on May 06, 2025)](http://www.sec.gov/Archives/edgar/data/2038185/000121390025039855/ea023887001ex6-2_jabez.htm) |
| 6.3 | [Unsecured Promissory Note in the principal sum of $250,000 of Jabez Biosciences, Inc. as Maker, Dated August 14, 2024 ((Incorporated by reference to Exhibit 6.3 to the Company's Annual Report on Form 1-K (File No. 24R-00990) filed on May 06, 2025)](http://www.sec.gov/Archives/edgar/data/2038185/000121390025039855/ea023887001ex6-3_jabez.htm) |
| 6.4 | [Unsecured Promissory Note in the principal sum of $250,000 of Jabez Biosciences, Inc. as Maker, Dated November 11, 2024 (Incorporated by reference to Exhibit 6.4 to the Company's Annual Report on Form 1-K (File No. 24R-00990) filed on May 06, 2025)](http://www.sec.gov/Archives/edgar/data/2038185/000121390025039855/ea023887001ex6-4_jabez.htm) |
| 6.5 | [Unsecured Promissory Note in the principal sum of $200,000 of Jabez Biosciences, Inc. as Maker, Dated April 29, 2025 (Incorporated by reference to Exhibit 6.5 to the Company's Annual Report on Form 1-K (File No. 24R-00990) filed on May 06, 2025)](http://www.sec.gov/Archives/edgar/data/2038185/000121390025039855/ea023887001ex6-5_jabez.htm) |
| 6.6\* | [Amendment to Unsecured Promissory Note in the principal sum of $200,000 of Jabez Biosciences, Inc. as Maker Dated June 29, 2025](ea025911301ex6-6_jabez.htm) |
| 6.7\* | [Amendment to Unsecured Promissory Note in the principal sum of $200,000 of Jabez Biosciences, Inc. as Maker Dated August 29, 2025](ea025911301ex6-7_jabez.htm) |
| 6.8\* | [Loan Conversion and Put Option Agreement of Jabez Biosciences , Inc. Dated May 29, 2025](ea025911301ex6-8_jabez.htm) |
| 6.9\* | [Subscription Agreement in the amount of $200,000, Jabez Biosciences, Inc. as Issuer, Dated November 14, 2024](ea025911301ex6-9_jabez.htm) |
| 6.10\* | [Subscription Agreement in the amount of $100,000, Jabez Biosciences, Inc. as Issuer, Dated January 21, 2025](ea025911301ex6-10_jabez.htm) |
| 6.11\* | [Subscription Agreement in the amount of $100,000, Jabez Biosciences, Inc. as Issuer, Dated February 24, 2025](ea025911301ex6-11_jabez.htm) |
| 6.12\* | [Subscription Agreement in the amount of $100,000, Jabez Biosciences, Inc. as Issuer, Dated March 25, 2025](ea025911301ex6-12_jabez.htm) |
| 6.13\* | [Subscription Agreement in the amount of $100,000, Jabez Biosciences, Inc. as Issuer, Dated April 28, 2025](ea025911301ex6-13_jabez.htm) |
| 6.14\* | [Subscription Agreement in the amount of $100,000, Jabez Biosciences, Inc. as Issuer, Dated May 28, 2025](ea025911301ex6-14_jabez.htm) |
| 6.15\* | [Subscription Agreement in the amount of $150,000, Jabez Biosciences, Inc. as Issuer, Dated June 27, 2025](ea025911301ex6-15_jabez.htm) |
| 6.16\* | [Subscription Agreement in the amount of $150,000, Jabez Biosciences, Inc. as Issuer, Dated July 28, 2025](ea025911301ex6-16_jabez.htm) |
| 6.17\* | [Subscription Agreement in the amount of $150,000, Jabez Biosciences, Inc. as Issuer, Dated August 29, 2025](ea025911301ex6-17_jabez.htm) |
| 6.18\* | [Subscription Agreement in the amount of $150,000, Jabez Biosciences, Inc. as Issuer, Dated September 26, 2025](ea025911301ex6-18_jabez.htm) |

---

\* Filed herewith.

**SIGNATURES**

Pursuant to the requirements of Regulation A, the issuer certifies that it has reasonable grounds to believe the information contained within this Form 1-SA is true and correct to the best of its knowledge and belief and has duly signed this Form 1-SA in Zionsville, IN on September 30, 2025.

---

| | | |
|:---|:---|:---|
|  | **JABEZ BIOSCIENCES, INC.** | **JABEZ BIOSCIENCES, INC.** |
|  | By: | /s/ Tamara Jovonovich |
| Date: September 30, 2025 |  | Tamara Jovonovich |
|  |  | President and Director<br> (Principal Executive Officer) |

---

## Ex1Sa-6

**Exhibit 6.6**

<u>Amendment to Promissory Note Maturity</u>

Effective June 29, 2025, this is an Amendment to that certain Promissory Note in the amount of Two Hundred Thousand Dollars ($200,000) hereinafter referred to as (the "Note") dated April 29, 2025 by and between Jabez Biosciences, Inc. ("Maker") and James Keith Bustin ("Payee").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Maker and Payee, attest, by signature below, that all accrued interest due on the Note was paid in
full on June 29, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The Maker and Payee hereby Amend the Note, without penalty, to provide that the outstanding average principal
balance of the Note shall accrue simple interest, beginning on June 30, 2025 at the rate 1.5% per month, which shall accrue and be paid
in full, along with all principal by Maker on August 29, 2025 (the "Maturity Date".)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Other than as specifically amended hereby, all other terms and provisions of the Note dated April 29,
2025 remain in full force and effect.

---

| | | | |
|:---|:---|:---|:---|
| Jabez Biosciences, Inc. | Jabez Biosciences, Inc. |  |  |
| By: | /s/ Tamara Jovonovich | By: | /s/ James Keith Bustin |
|  | Tamara Jovonovich, CEO |  | James Keith Bustin |

---

## Ex1Sa-6

**Exhibit 6.7**

<u>Amendment to Promissory Note Maturity</u>

Effective August 29, 2025, this is an Amendment to that certain Promissory Note in the amount of Two Hundred Thousand Dollars ($200,000) hereinafter referred to as (the "Note") dated April 29, 2025 by and between Jabez Biosciences, Inc. ("Maker") and James Keith Bustin ("Payee").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Maker and Payee, attest, by signature below, that all accrued interest due on the Note was paid in
full on August 29, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The Maker and Payee hereby Amend the Note, without penalty, to provide that the outstanding average principal
balance of the Note shall accrue simple interest, beginning on August 30, 2025 at the rate 1.5% per month, which shall accrue and be paid
in full, along with all principal by Maker on October 29, 2025 (the "Maturity Date".)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Other than as specifically amended hereby, all other terms and provisions of the Note dated April 29,
2025 remain in full force and effect.

---

| | | | |
|:---|:---|:---|:---|
| Jabez Biosciences, Inc. | Jabez Biosciences, Inc. |  |  |
| By: | /s/ Tamara Jovonovich | By: | /s/ James Keith Bustin |
|  | Tamara Jovonovich, CEO |  | James Keith Bustin |

---

## Ex1Sa-6

**Exhibit 6.8**

**<u>LOAN CONVERSION AND PUT OPTION AGREEMENT</u>**

This Agreement is entered into on May 29, 2025, by and between Jabez Biosciences, Inc, ("Company") and Brett Pylant ("Holder").

&nbsp;&nbsp;&nbsp;&nbsp;1. The Parties are parties to that certain Promissory Note and Share Purchase Agreement ("Agreement") dated November 11, 2024, including
a loan ("Note") in the amount of Two Hundred Fifty Thousand Dollars ($250,000) ("Principal Sum")

&nbsp;&nbsp;&nbsp;&nbsp;2. The Parties agree that Holder hereby converts the Principal Sum of the Note into One Million
(1,000,000) shares ("Shares") of Common Stock of the Company, effective as of the date hereof. All accrued interest under
the Note will be paid to Holder within 10 days from the date hereof. Said Shares are restricted stock of Company and are subject to a
legal 6 month holding period following any public listing of Company's stock. Holder hereby agrees to accept the Shares as full
and complete satisfaction of the Principal Sum due under the Note.

&nbsp;&nbsp;&nbsp;&nbsp;3. The Parties further agree that Holder shall have a "put option" ("Put")
entitling Holder to require the Company to purchase Two Hundred and Fifty Thousand (250,000) of the Shares back from him for the repurchase
price of Three Hundred Thousand Dollars ($300,000) on the 6 month anniversary of the execution of this Agreement. Holder may exercise
this right by providing written notice of his intent to exercise this Put no later than 30 days prior to the date such repurchase is
to occur.

&nbsp;&nbsp;&nbsp;&nbsp;4. Holder represents that he is a sophisticated and accredited investor as that term is defined
under applicable state and federal securities laws and has the knowledge and experience to fully understand the risks associated with
a transaction of this nature.

&nbsp;&nbsp;&nbsp;&nbsp;5. This is the full and final agreement between the Parties with respect to the matters set
forth herein, however, the Parties agree to execute any and all other documents, including stock powers, and other related instruments,
necessary to fully effectuate all transactions contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;6. This transaction shall be governed in all respects under Florida law and venue in any action
arising out of or related to this Note or transaction shall lie exclusively in the Courts in and for Orange County, Florida, for all
purposes.

---

| | | |
|:---|:---|:---|
| Jabez Biosciences, Inc. | Jabez Biosciences, Inc. | Holder: |
| By: | /s/ Tamara Jovonovich | /s/ Brent Pylant |
|  | Tamara Jovonovich, President | Brent Pylant |

---

## Ex1Sa-6

**Exhibit 6.9**

**JABEZ BIOSCIENCES, INC.**

**$3,000,000 PRIVATE OFFERING OF COMMON STOCK**

**<u>OFFERING MEMORANDUM AND SUBSCRIPTION AGREEMENT</u>**

This Subscription Agreement (this "Agreement") is dated as of 11/15/2024 Between Jabez Biosciences, Inc., a Florida corporation ("Jabez" or the "Company") and MEDTEK, LLC, a Florida limited liability company, ("Purchaser").

WHEREAS, the Company is in the process of selling up to $3,000,000 of Common Stock to certain accredited and/or sophisticated investors, with a minimum purchase amount of $500.

WHEREAS, the Common Stock is being sold to select accredited and non-accredited but sophisticated investors in a private offering under Regulation D, Rule 506(b) as of August 02, 2024; and

WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to Purchaser, and Purchaser desires to purchase from the Company, certain of those Common Stock of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

<u>THE OFFERING</u>

Terms of Offering. The Company is offering Class "A" Common Stock at $1 per share.

<u>Common Stock</u>. The Company is selling Class "A" Common Stock (the "Shares"), in advance of its planned public markets listing, at a price of $1 per share. The Company is planning to undertake a public listing on either a national exchange or the OTCQB or OTCQX within 12 months from the date of this offering. The Shares, once issued, will be restricted for a minimum of 6 months under applicable federal securities laws.

<u>PURCHASE AND SALE</u>

<u>Purchase Amount</u>. the Company agrees to sell, and Purchaser agrees to purchase:

a total of <u>200,000</u> Shares from Company at $1 per share

for a total purchase amount of $<u>200,000</u>.

Purchaser shall deliver to the Company, via wire transfer or a certified check, immediately available funds equal to such Purchaser's Purchase Amount as set forth herein.

<u>THE COMPANY</u>

Jabez Biosciences is a Clinical Stage Biotechnology company developing liquid and solid tumor therapies. The company's lead technology is a dihydroorotate dehydrogenase (DHODH) small molecule inhibitor. This proprietary small molecule is easily synthesized, encapsulated for oral dosing, and stores at room temperature. Strong pre-clinical data suggests that the Jabez molecule may be a safe and effective therapeutic in humans for a number of solid and liquid tumors, allowing for an Investigational New Drug application. Jabez's novel DHODH compound was created and developed by world class scientists at The Ohio State University James Cancer Hospital and Solove Research Institute. The drug inhibits tumor cell growth and survival by not allowing cells to repair and multiply. This treatment is considered a *targeted* therapy (unlike a chemotherapy) because it only effects proliferative diseases where the diseased cells need to grow at accelerated rates, such as cancer. The way normal cells repair and multiply is unaffected. The drug is Phase I ready with anticipated IND filing in June 2024 and anticipated study start in September/October 2024.

The DHODH inhibitor is anticipated to be a First Line Treatment, for several solid and liquid tumor types, many qualifying for FDA fast track, priority review, and orphan status, creating "first in the que" reviews from the FDA and shorter times to approval. The DHODH inhibitor class has become an increasingly popular inhibitor in recent years. The FDA approved multiple DHODH drug programs such as Sanofi's Arava®, indicated for rheumatoid arthritis, and Aubagio® indicated for multiple sclerosis.

The safety and efficacy of DHODH class is well known in the oncology space for blocking cell cycle progression and inducing apoptosis, which has led companies like Johnson & Johnson Innovative Medicine (J&J, formerly Janssen) to invest in their own DHODH program for Acute Myeloid Leukemia (AML). J&J's multi-year investment has no doubt stirred the interest of Big Pharma in this class of drug and should help validate Jabez' own program while increasing its intrinsic value. Interest in Jabez by other Big Pharma companies looking to expand their small molecule platforms may have some comfort level in the future because of J&J's program.

**<u>Officers and Directors</u>**

<u>Tamara Jovonovich – President, Chief Executive Officer and Director</u>. Tamara Jovonovich received a B.S. in Chemistry and a B.S.in Fine Arts from the University of Central Florida, 1996, and went on to earn her PhD. in Biophysical Chemistry at the University of Washington, 2000. Tamara completed her post-doctoral research at Stanford University and Lectured at San Jose University, before entering the pharmaceutical industry in Palo Alto, CA, 2004. Tamara has remained in the industry for 20 years, working at start-up and medium cap pharma companies across multiple disciplines for example Alexza Pharmaceuticals (acquired by Ferrer), Cypress Pharmaceuticals, and Pernix Therapeutics.

<u>Robert Lewis – Chief Operating Officer and Director</u>. Robert Lewis earned his B.S. in Chemistry & Biology from Columbia College. Robert went on to work at global companies like Teva and Sigma as well as mid-tier and small pharma. Robert was an equity partner of Cypress Pharmaceutical and held the position of CSO, heading the departments of Scientific Affairs, Clinical Affairs, Regulatory Affairs, and Domestic and International Business Development. Cypress sold to a publicly traded company (Pernix) in 2012 for $102M. Additionally, Robert is an equity partner and sits on the BOD in other start-up companies in Pharma and Medical Device fields.

<u>Brian Cogley – Chief Financial Officer</u>. Brian Cogley is a senior-level financial executive with over 15 years of experience in corporate finance and accounting across a variety of industries, including life sciences, pharmaceuticals, financial services, and manufacturing.

<u>Bruce A. Cassidy, Independent Director.</u> Bruce Cassidy joined our Board of Directors in August of 2024. Since 2017 he has been the Chairman of the Board of Sarasota Green Group. He currently serves on other boards for various companies, including as chairman of the board of each of Arboreta Healthcare (August 2020), KeyStar Corporation (d/b/a Zensports) (August 2022), Loop Media, Inc. (Board Member February 2020 and Chairman January 2021) and as a member of the board of Oragenics, Inc. (October 2023). Mr. Cassidy was chosen to serve as a member of our Board of Directors due to his extensive leadership and business experience and as a CEO of a large company, as well as his service on other boards of directors.

<u>Martin Lewis, Director.</u> Mr. Lewis joined our Board of Directors in August of 2024. Mr. Lewis has over 40 years of experience in Accounting and is a Certified Public Accountant. Mr. Lewis joined his current firm, Lewis, Kaufman & Co., P.C., in 1983. Mr. Lewis has been very active in the professional accounting field, having active memberships for a number of years with the American Institute of C.P.A.s, Texas Society of C.P.A.s, National Society of Accountants for Cooperatives and the Management of Accounting Practice - West Texas Chapter.

<u>REPRESENTATIONS AND AGREEMENTS OF THE PARTIES</u>

<u>Company Representations.</u> The Company is a duly formed and valid entity existing under Florida law. The Company has all right and title to enter into this Agreement without condition or reservation. The Company has the full legal right and authority to issue the Shares purchased by Purchaser hereunder.

<u>Purchaser Representations.</u> Purchaser represents that he or she has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment and has so evaluated the merits and risks of such investment. Purchaser has been afforded full and complete opportunity to receive and review all business and financial information regarding the Company and its business and is satisfied as to the same. Purchaser is able to bear the economic risk of this investment and, at the present time, is able to afford a complete loss of such investment. Purchaser has had the opportunity to seek the advice of legal or financial advisers regarding this investment and has carefully reviewed all Risk Factors associated with this highly speculative and risky investment.

<u>RISK FACTORS</u>

The purchase of Shares is subject to a number of significant risks in the Company or businesses in which the Company operates. The following risk factors should be carefully considered.

**Investments in small businesses and start-up companies are often risky.**

Small businesses may depend heavily upon a single customer, supplier, or employee whose departure would seriously damage the Company's profitability. The demand for the Company's product may be seasonal or be impacted by the overall economy, or the Company could face other risks that are specific to its industry or type of business. The Company may also have difficulty competing against larger companies who can negotiate for better prices from suppliers, produce goods and services on a large scale more economically, or take advantage of bigger marketing budgets. Furthermore, a small business could face risks from lawsuits, governmental regulations, and other potential impediments to growth.

**The Company may need additional capital, which may not be available.**

The Company may require funds in excess of its existing cash resources to fund operating deficits, develop new products or services, establish, and expand its marketing capabilities, and finance general and administrative activities. Due to market conditions at the time the Company may need additional funding, or due to its financial condition at that time, it is possible that the Company will be unable to obtain additional funding as and when it needs it and that could significantly affect the success of the Company.

**The Company's management has broad discretion in how the Company use the net proceeds of an offering.**

The Company's management will have considerable discretion over the use of proceeds from their offering. You may not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.

**The Company faces significant competition and operates in a highly regulated industry.**

The Company operates in the areas of bio-technology products and services, which is a highly competitive industry. There is substantial competition in the industry and many of the competitors are larger companies with deeper resources than the Company. Therefore, the Company will face stiff competition as it seeks to grow and execute its business plan. In addition, the Company operates in a highly regulated industry and as a result can incur significant costs and regulatory hurdles in bringing its products to market. Competitors may be better financed and able to overcome these regulatory hurdles and as such the Company may be at a disadvantage in the marketplace as a result.

**The Company may not be able to manage its potential growth.**

For the Company to succeed, it needs to experience significant expansion. There can be no assurance that it will achieve this expansion. This expansion, if accomplished, may place a significant strain on the Company's management, operational and financial resources. To manage any material growth, the Company will be required to implement operational and financial systems, procedures and controls. It will also be required to expand its finance, administrative and operations staff. There can be no assurance that the Company's current and planned personnel, systems, procedures and controls will be adequate to support its future operations at any increased level. The Company's failure to manage growth effectively could have a material adverse effect on its business, results of operations and financial condition.

**The Company's success relies on market acceptance.**

While the Company believes that there will be significant customer demand for its products/services, there is no assurance that there will be broad market acceptance of the Company's product offerings. In such event, there may be a material adverse effect on the Company's results of operations and financial condition, and the Company may not be able to achieve its business goals.

**We have a limited operating history, which may make it difficult for investors to predict future performance based on current operations.**

We have a limited operating history upon which investors may base an evaluation of our potential future performance. In particular, our limited staff and operating history means that there is a high degree of uncertainty regarding our ability to (i) develop and commercialize our technologies and proposed products (ii) obtain regulatory approval to commence the marketing of our products, (iii) manage growth, (iv) achieve market acceptance or insurance reimbursement for any of our proposed products, if successfully developed, or (v) respond to competition. As a result, there can be no assurance that we will be able to develop or maintain consistent revenue sources, or that our operations will be profitable and/or generate positive cash flows.

Any forecasts we make about our operations may prove to be inaccurate. We must, among other things, determine appropriate risks, rewards, and level of investment in our product lines, respond to economic and market variables outside of our control, respond to competitive developments and continue to attract, retain, and motivate qualified employees. There can be no assurance that we will be successful in meeting these challenges and addressing such risks and the failure to do so could have a materially adverse effect on our business, results of operations, and financial condition. Our prospects must be considered in light of the risks, expenses, and difficulties frequently encountered by companies in the early stage of development. As a result of these risks, challenges, and uncertainties, the value of your investment could be significantly reduced or completely lost.

**If we are unable to successfully identify, develop, and commercialize any product candidates, or experience significant delays in doing so, our business, financial condition, and results of operations will be materially adversely affected.**

Our ability to generate revenue from sales of any of our product candidates, which we do not expect to occur for at least the next several years, if ever, will depend heavily on the timely and successful identification, development, regulatory approval, and eventual commercialization of any such product candidates, which may never occur. To date, we have not generated revenue from sales of any products, and we may never be able to develop, obtain regulatory approval for, or commercialize a marketable product. Before we generate any revenue from product sales of any of our current or potential future product candidates, we will need to manage preclinical, clinical, and manufacturing activities, including undertaking significant clinical development, obtain regulatory approval in multiple jurisdictions, establish manufacturing supply, including commercial manufacturing supply, and build a commercial organization, which will require substantial investment and significant marketing efforts. We may never receive regulatory approval for any of our product candidates, which would prevent us from marketing, promoting, or selling any of our product candidates and generating revenue.

**Our success depends on our ability to protect our intellectual property rights and proprietary technologies, and we may not be able to protect our intellectual property rights throughout the world.**

Patent rights are generally national or regional rights. The filing, prosecution, maintenance, and defense of patent rights on our platform technologies and product candidates worldwide would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may have a different scope and strength than do those in the United States. In addition, the laws of some foreign countries, particularly certain developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our intellectual property rights in all countries outside the United States or from making, using, selling, or importing products made using our intellectual property rights in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained intellectual property rights, including patent protection, to develop their own products and may also export otherwise infringing products to territories where we have intellectual property rights, including patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products and our patent or other intellectual property rights may not be effective or adequate to prevent them from competing.

**The Company's founders, directors and executive officers own or control a majority of the Company.**

Additionally, the holdings of the Company's directors and executive officers may increase in the future upon vesting or other maturation of exercise rights under any of the options or warrants they may hold or in the future be granted or if they otherwise acquire additional interest in the Company. The interests of such persons may differ from the interests of the Company's other stockholders, including purchasers of securities in the offering. As a result, in addition to their board seats and offices, such persons will have significant influence over and control all corporate actions requiring stockholder approval, irrespective of how the Company's other stockholders, including purchasers in the offering, may vote.

**The Company may not be able to accomplish its public listing, and a market may not develop for the Shares.**

The Company is planning to become publicly listed within 12 months from the date hereof. However, there is no assurance that such public listing will ever occur or that a market will ever develop for the sale of the Shares in either event.

<u>MISCELLANEOUS</u>

<u>Entire Agreement</u>. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Agreement.

<u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on date of transmission if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

<u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

<u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. Neither party may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party.

<u>No Third-Party Beneficiaries</u>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by any other Person.

<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Florida, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this shall be commenced exclusively in the state and federal courts sitting in Volusia County, Florida.

<u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

<u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a ".pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or ".pdf" signature page is an original thereof.

<u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

**<u>WAIVER OF JURY TRIAL</u>. <u>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</u>**

IN WITNESS WHEREOF, the parties hereto have caused this Subscription Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

---

| | |
|:---|:---|
| **JABEZ BIOSCIENCES, INC.** | **JABEZ BIOSCIENCES, INC.** |
| By: | /s/ Tamara Jovonovich |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tamara Jovonovich, President and CEO | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tamara Jovonovich, President and CEO |

---

**PURCHASER(S) / AUTHORIZED SIGNER**

---

| | | |
|:---|:---|:---|
| Company Name: | MEDTEK, LLC |  |
| Signature: | /s/ Martin Lewis |  |
| Print Name: | Martin Lewis |  |
|  | First Last |  |
| Title: | Manager |  |
| SSN# or FEIN: | To be provided |  |
| Street Address: | 2308 W 5<sup>th</sup> Street |  |
| City: | <u>Plainview</u> | State: <u>TX</u> Zip Code: <u>79072</u> |
| Phone: |  |  |
| Email: | mcl@cpaontheweb.com |  |

---

**REGISTRATION TYPE:** (Select only one)

☐ Individual ☒ Company ☐ Joint Tenants ☐ Custodian IRA Account F/B/O (fill in below)

☐ Trust / Trustee: ______________________________________________Trust Date: ______________________

**IF CUSTODIAL IRA, PLEASE COMPLETE**

Authorized Signer: _______________________________________________________________________________

Registration Name: _______________________________________________________________________________

Tax ID #: ___________________________________________Phone #: ____________________________________

Address: _______________________________________________________________________________________

## Ex1Sa-6

**Exhibit 6.10**

**JABEZ BIOSCIENCES, INC.**

**$3,000,000 PRIVATE OFFERING OF COMMON STOCK**

**<u>OFFERING MEMORANDUM AND SUBSCRIPTION AGREEMENT</u>**

This Subscription Agreement (this "<u>Agreement</u>") is dated as of <u>1/21/25</u> between Jabez Biosciences, Inc., a Florida corporation ("Jabez" or the "<u>Company</u>") and MedTek, LLC, a Florida limited liability company, ("<u>Purchaser</u>").

WHEREAS, the Company is in the process of selling up to $3,000,000 of Common Stock to certain accredited and/or sophisticated investors, with a minimum purchase amount of $500.

WHEREAS, the Common Stock is being sold to select accredited and non-accredited but sophisticated investors in a private offering under Regulation D, Rule 506(b) as of August 02, 2024; and

WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to Purchaser, and Purchaser desires to purchase from the Company, certain of those Common Stock of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

<u>THE OFFERING</u>

Terms of Offering. The Company is offering Class "A" Common Stock at $1 per share.

<u>Common Stock</u>. The Company is selling Class "A" Common Stock (the "Shares"), in advance of its planned public markets listing, at a price of $1 per share. The Company is planning to undertake a public listing on either a national exchange or the OTCQB or OTCQX within 12 months from the date of this offering. The Shares, once issued, will be restricted for a minimum of 6 months under applicable federal securities laws.

<u>PURCHASE AND SALE</u>

<u>Purchase Amount</u>. the Company agrees to sell, and Purchaser agrees to purchase:

a total of <u>100,000</u> Shares from Company at $1 per share

for a total purchase amount of $<u>100,000</u>.

Purchaser shall deliver to the Company, via wire transfer or a certified check, immediately available funds equal to such Purchaser's Purchase Amount as set forth herein.

<u>THE COMPANY</u>

Jabez Biosciences is a Clinical Stage Biotechnology company developing liquid and solid tumor therapies. The company's lead technology is a dihydroorotate dehydrogenase (DHODH) small molecule inhibitor. This proprietary small molecule is easily synthesized, encapsulated for oral dosing, and stores at room temperature. Strong pre-clinical data suggests that the Jabez molecule may be a safe and effective therapeutic in humans for a number of solid and liquid tumors, allowing for an Investigational New Drug application. Jabez's novel DHODH compound was created and developed by world class scientists at The Ohio State University James Cancer Hospital and Solove Research Institute . The drug inhibits tumor cell growth and survival by not allowing cells to repair and multiply. This treatment is considered a *targeted* therapy (unlike a chemotherapy) because it only effects proliferative diseases where the diseased cells need to grow at accelerated rates, such as cancer. The way normal cells repair and multiply is unaffected. The drug is Phase I ready with anticipated IND filing in June 2024 and anticipated study start in September/October 2024.

The DHODH inhibitor is anticipated to be a First Line Treatment, for several solid and liquid tumor types, many qualifying for FDA fast track, priority review, and orphan status, creating "first in the que" reviews from the FDA and shorter times to approval. The DHODH inhibitor class has become an increasingly popular inhibitor in recent years. The FDA approved multiple DHODH drug programs such as Sanofi's Arava®, indicated for rheumatoid arthritis, and Aubagio® indicated for multiple sclerosis.

The safety and efficacy of DHODH class is well known in the oncology space for blocking cell cycle progression and inducing apoptosis, which has led companies like Johnson & Johnson Innovative Medicine (J&J, formerly Janssen) to invest in their own DHODH program for Acute Myeloid Leukemia (AML). J&J's multi-year investment has no doubt stirred the interest of Big Pharma in this class of drug and should help validate Jabez' own program while increasing its intrinsic value. Interest in Jabez by other Big Pharma companies looking to expand their small molecule platforms may have some comfort level in the future because of J&J's program.

**<u>Officers and Directors</u>**

<u>Tamara Jovonovich – President, Chief Executive Officer and Director</u>. Tamara Jovonovich received a B.S. in Chemistry and a B.S.in Fine Arts from the University of Central Florida, 1996, and went on to earn her PhD. in Biophysical Chemistry at the University of Washington, 2000. Tamara completed her post-doctoral research at Stanford University and Lectured at San Jose University, before entering the pharmaceutical industry in Palo Alto, CA, 2004. Tamara has remained in the industry for 20 years, working at start-up and medium cap pharma companies across multiple disciplines for example Alexza Pharmaceuticals (acquired by Ferrer), Cypress Pharmaceuticals, and Pernix Therapeutics.

<u>Robert Lewis – Chief Operating Officer and Director</u>. Robert Lewis earned his B.S. in Chemistry & Biology from Columbia College. Robert went on to work at global companies like Teva and Sigma as well as mid-tier and small pharma. Robert was an equity partner of Cypress Pharmaceutical and held the position of CSO, heading the departments of Scientific Affairs, Clinical Affairs, Regulatory Affairs, and Domestic and International Business Development. Cypress sold to a publicly traded company (Pernix) in 2012 for $102M. Additionally, Robert is an equity partner and sits on the BOD in other start-up companies in Pharma and Medical Device fields.

<u>Brian Cogley – Chief Financial Officer</u>. Brian Cogley is a senior-level financial executive with over 15 years of experience in corporate finance and accounting across a variety of industries, including life sciences, pharmaceuticals, financial services, and manufacturing.

<u>Bruce A. Cassidy, Independent Director.</u> Bruce Cassidy joined our Board of Directors in August of 2024. Since 2017 he has been the Chairman of the Board of Sarasota Green Group. He currently serves on other boards for various companies, including as chairman of the board of each of Arboreta Healthcare (August 2020), KeyStar Corporation (d/b/a Zensports) (August 2022), Loop Media, Inc. (Board Member February 2020 and Chairman January 2021) and as a member of the board of Oragenics, Inc. (October 2023). Mr. Cassidy was chosen to serve as a member of our Board of Directors due to his extensive leadership and business experience and as a CEO of a large company, as well as his service on other boards of directors.

<u>Martin Lewis, Director.</u> Mr. Lewis joined our Board of Directors in August of 2024. Mr. Lewis has over 40 years of experience in Accounting and is a Certified Public Accountant. Mr. Lewis joined his current firm, Lewis, Kaufman & Co., P.C., in 1983. Mr. Lewis has been very active in the professional accounting field, having active memberships for a number of years with the American Institute of C.P.A.s, Texas Society of C.P.A.s, National Society of Accountants for Cooperatives and the Management of Accounting Practice - West Texas Chapter.

<u>REPRESENTATIONS AND AGREEMENTS OF THE PARTIES</u>

<u>Company Representations.</u> The Company is a duly formed and valid entity existing under Florida law. The Company has all right and title to enter into this Agreement without condition or reservation. The Company has the full legal right and authority to issue the Shares purchased by Purchaser hereunder.

<u>Purchaser Representations.</u> Purchaser represents that he or she has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment and has so evaluated the merits and risks of such investment. Purchaser has been afforded full and complete opportunity to receive and review all business and financial information regarding the Company and its business and is satisfied as to the same. Purchaser is able to bear the economic risk of this investment and, at the present time, is able to afford a complete loss of such investment. Purchaser has had the opportunity to seek the advice of legal or financial advisers regarding this investment and has carefully reviewed all Risk Factors associated with this highly speculative and risky investment.

<u>RISK FACTORS</u>

The purchase of Shares is subject to a number of significant risks in the Company or businesses in which the Company operates. The following risk factors should be carefully considered.

**Investments in small businesses and start-up companies are often risky.**

Small businesses may depend heavily upon a single customer, supplier, or employee whose departure would seriously damage the Company's profitability. The demand for the Company's product may be seasonal or be impacted by the overall economy, or the Company could face other risks that are specific to its industry or type of business. The Company may also have difficulty competing against larger companies who can negotiate for better prices from suppliers, produce goods and services on a large scale more economically, or take advantage of bigger marketing budgets. Furthermore, a small business could face risks from lawsuits, governmental regulations, and other potential impediments to growth.

**The Company may need additional capital, which may not be available.**

The Company may require funds in excess of its existing cash resources to fund operating deficits, develop new products or services, establish, and expand its marketing capabilities, and finance general and administrative activities. Due to market conditions at the time the Company may need additional funding, or due to its financial condition at that time, it is possible that the Company will be unable to obtain additional funding as and when it needs it and that could significantly affect the success of the Company.

**The Company's management has broad discretion in how the Company use the net proceeds of an offering.**

The Company's management will have considerable discretion over the use of proceeds from their offering. You may not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.

**The Company faces significant competition and operates in a highly regulated industry.**

The Company operates in the areas of bio-technology products and services, which is a highly competitive industry. There is substantial competition in the industry and many of the competitors are larger companies with deeper resources than the Company. Therefore, the Company will face stiff competition as it seeks to grow and execute its business plan. In addition, the Company operates in a highly regulated industry and as a result can incur significant costs and regulatory hurdles in bringing its products to market. Competitors may be better financed and able to overcome these regulatory hurdles and as such the Company may be at a disadvantage in the marketplace as a result.

**The Company may not be able to manage its potential growth.**

For the Company to succeed, it needs to experience significant expansion. There can be no assurance that it will achieve this expansion. This expansion, if accomplished, may place a significant strain on the Company's management, operational and financial resources. To manage any material growth, the Company will be required to implement operational and financial systems, procedures and controls. It will also be required to expand its finance, administrative and operations staff. There can be no assurance that the Company's current and planned personnel, systems, procedures and controls will be adequate to support its future operations at any increased level. The Company's failure to manage growth effectively could have a material adverse effect on its business, results of operations and financial condition.

**The Company's success relies on market acceptance.**

While the Company believes that there will be significant customer demand for its products/services, there is no assurance that there will be broad market acceptance of the Company's product offerings. In such event, there may be a material adverse effect on the Company's results of operations and financial condition, and the Company may not be able to achieve its business goals.

**We have a limited operating history, which may make it difficult for investors to predict future performance based on current operations.**

We have a limited operating history upon which investors may base an evaluation of our potential future performance. In particular, our limited staff and operating history means that there is a high degree of uncertainty regarding our ability to (i) develop and commercialize our technologies and proposed products (ii) obtain regulatory approval to commence the marketing of our products, (iii) manage growth, (iv) achieve market acceptance or insurance reimbursement for any of our proposed products, if successfully developed, or (v) respond to competition. As a result, there can be no assurance that we will be able to develop or maintain consistent revenue sources, or that our operations will be profitable and/or generate positive cash flows.

Any forecasts we make about our operations may prove to be inaccurate. We must, among other things, determine appropriate risks, rewards, and level of investment in our product lines, respond to economic and market variables outside of our control, respond to competitive developments and continue to attract, retain, and motivate qualified employees. There can be no assurance that we will be successful in meeting these challenges and addressing such risks and the failure to do so could have a materially adverse effect on our business, results of operations, and financial condition. Our prospects must be considered in light of the risks, expenses, and difficulties frequently encountered by companies in the early stage of development. As a result of these risks, challenges, and uncertainties, the value of your investment could be significantly reduced or completely lost.

 ****

**If we are unable to successfully identify, develop, and commercialize any product candidates, or experience significant delays in doing so, our business, financial condition, and results of operations will be materially adversely affected.**

Our ability to generate revenue from sales of any of our product candidates, which we do not expect to occur for at least the next several years, if ever, will depend heavily on the timely and successful identification, development, regulatory approval, and eventual commercialization of any such product candidates, which may never occur. To date, we have not generated revenue from sales of any products, and we may never be able to develop, obtain regulatory approval for, or commercialize a marketable product. Before we generate any revenue from product sales of any of our current or potential future product candidates, we will need to manage preclinical, clinical, and manufacturing activities, including undertaking significant clinical development, obtain regulatory approval in multiple jurisdictions, establish manufacturing supply, including commercial manufacturing supply, and build a commercial organization, which will require substantial investment and significant marketing efforts. We may never receive regulatory approval for any of our product candidates, which would prevent us from marketing, promoting, or selling any of our product candidates and generating revenue.

**Our success depends on our ability to protect our intellectual property rights and proprietary technologies, and we may not be able to protect our intellectual property rights throughout the world.**

Patent rights are generally national or regional rights. The filing, prosecution, maintenance, and defense of patent rights on our platform technologies and product candidates worldwide would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may have a different scope and strength than do those in the United States. In addition, the laws of some foreign countries, particularly certain developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our intellectual property rights in all countries outside the United States or from making, using, selling, or importing products made using our intellectual property rights in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained intellectual property rights, including patent protection, to develop their own products and may also export otherwise infringing products to territories where we have intellectual property rights, including patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products and our patent or other intellectual property rights may not be effective or adequate to prevent them from competing.

**The Company's founders, directors and executive officers own or control a majority of the Company.**

Additionally, the holdings of the Company's directors and executive officers may increase in the future upon vesting or other maturation of exercise rights under any of the options or warrants they may hold or in the future be granted or if they otherwise acquire additional interest in the Company. The interests of such persons may differ from the interests of the Company's other stockholders, including purchasers of securities in the offering. As a result, in addition to their board seats and offices, such persons will have significant influence over and control all corporate actions requiring stockholder approval, irrespective of how the Company's other stockholders, including purchasers in the offering, may vote.

**The Company may not be able to accomplish its public listing, and a market may not develop for the Shares.**

The Company is planning to become publicly listed within 12 months from the date hereof. However, there is no assurance that such public listing will ever occur or that a market will ever develop for the sale of the Shares in either event.

<u>MISCELLANEOUS</u>

<u>Entire Agreement</u>. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Agreement.

<u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on date of transmission if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

<u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

<u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. Neither party may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party.

<u>No Third-Party Beneficiaries</u>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by any other Person.

<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Florida, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this shall be commenced exclusively in the state and federal courts sitting in Volusia County, Florida.

<u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

<u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a ".pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or ".pdf" signature page is an original thereof.

<u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

**<u>WAIVER OF JURY TRIAL</u>. <u>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</u>**

IN WITNESS WHEREOF, the parties hereto have caused this Subscription Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

---

| | |
|:---|:---|
| **JABEZ BIOSCIENCES, INC.** | **JABEZ BIOSCIENCES, INC.** |
| By: | /s/ Tamara Jovonovich |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tamara Jovonovich, President and CEO | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tamara Jovonovich, President and CEO |

---

**PURCHASER(S) / AUTHORIZED SIGNER**

---

| | |
|:---|:---|
| Company Name: | MedTek, LLC |
| Signature: | /s/ Jim Bullard |
| Print Name: | Jim Bullard |
|  | First Last |
| Title: | Manager |
| SSN# or FEIN: |  |
| Street Address: | 2308 W 5<sup>th</sup> Street |
| City: | Plainview, TX 79072 |
| Phone: | 806-777- 1158 |
| Email: | jbullard1@aol.com |

---

**REGISTRATION TYPE:** (Select only one)

☐ Individual ☒ Company ☐ Joint Tenants ☐ Custodian IRA Account F/B/O (fill in below)

☐ Trust / Trustee: ________________________________________________ Trust Date: ______________________

**IF CUSTODIAL IRA, PLEASE COMPLETE**

Authorized Signer: _______________________________________________________________________________

Registration Name: _______________________________________________________________________________

Tax ID #: ___________________________________________ Phone #: ____________________________________

Address: _______________________________________________________________________________________

## Ex1Sa-6

**Exhibit 6.11**

**JABEZ BIOSCIENCES, INC.**

**$3,000,000 PRIVATE OFFERING OF COMMON STOCK**

**<u>OFFERING MEMORANDUM AND SUBSCRIPTION AGREEMENT</u>**

This Subscription Agreement (this "<u>Agreement</u>") is dated as of <u>February 24, 2025</u> between Jabez Biosciences, Inc., a Florida corporation ("Jabez" or the "<u>Company</u>") and MedTek, LLC, a Florida limited liability company, ("<u>Purchaser</u>").

WHEREAS, the Company is in the process of selling up to $3,000,000 of Common Stock to certain accredited and/or sophisticated investors, with a minimum purchase amount of $500.

WHEREAS, the Common Stock is being sold to select accredited and non-accredited but sophisticated investors in a private offering under Regulation D, Rule 506(b) as of August 02, 2024; and

WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to Purchaser, and Purchaser desires to purchase from the Company, certain of those Common Stock of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

<u>THE OFFERING</u>

Terms of Offering. The Company is offering Class "A" Common Stock at $1 per share.

<u>Common Stock</u>. The Company is selling Class "A" Common Stock (the "Shares"), in advance of its planned public markets listing, at a price of $1 per share. The Company is planning to undertake a public listing on either a national exchange or the OTCQB or OTCQX within 12 months from the date of this offering. The Shares, once issued, will be restricted for a minimum of 6 months under applicable federal securities laws.

<u>PURCHASE AND SALE</u>

<u>Purchase Amount</u>. the Company agrees to sell, and Purchaser agrees to purchase:

a total of <u>100,000</u> Shares from Company at $1 per share

for a total purchase amount of $<u>100,000</u>.

Purchaser shall deliver to the Company, via wire transfer or a certified check, immediately available funds equal to such Purchaser's Purchase Amount as set forth herein.

<u>THE COMPANY</u>

Jabez Biosciences is a Clinical Stage Biotechnology company developing liquid and solid tumor therapies. The company's lead technology is a dihydroorotate dehydrogenase (DHODH) small molecule inhibitor. This proprietary small molecule is easily synthesized, encapsulated for oral dosing, and stores at room temperature. Strong pre-clinical data suggests that the Jabez molecule may be a safe and effective therapeutic in humans for a number of solid and liquid tumors, allowing for an Investigational New Drug application. Jabez's novel DHODH compound was created and developed by world class scientists at The Ohio State University James Cancer Hospital and Solove Research Institute . The drug inhibits tumor cell growth and survival by not allowing cells to repair and multiply. This treatment is considered a *targeted* therapy (unlike a chemotherapy) because it only effects proliferative diseases where the diseased cells need to grow at accelerated rates, such as cancer. The way normal cells repair and multiply is unaffected. The drug is Phase I ready with anticipated IND filing in June 2024 and anticipated study start in September/October 2024.

The DHODH inhibitor is anticipated to be a First Line Treatment, for several solid and liquid tumor types, many qualifying for FDA fast track, priority review, and orphan status, creating "first in the que" reviews from the FDA and shorter times to approval. The DHODH inhibitor class has become an increasingly popular inhibitor in recent years. The FDA approved multiple DHODH drug programs such as Sanofi's Arava®, indicated for rheumatoid arthritis, and Aubagio® indicated for multiple sclerosis.

The safety and efficacy of DHODH class is well known in the oncology space for blocking cell cycle progression and inducing apoptosis, which has led companies like Johnson & Johnson Innovative Medicine (J&J, formerly Janssen) to invest in their own DHODH program for Acute Myeloid Leukemia (AML). J&J's multi-year investment has no doubt stirred the interest of Big Pharma in this class of drug and should help validate Jabez' own program while increasing its intrinsic value. Interest in Jabez by other Big Pharma companies looking to expand their small molecule platforms may have some comfort level in the future because of J&J's program.

**<u>Officers and Directors</u>**

<u>Tamara Jovonovich – President, Chief Executive Officer and Director</u>. Tamara Jovonovich received a B.S. in Chemistry and a B.S.in Fine Arts from the University of Central Florida, 1996, and went on to earn her PhD. in Biophysical Chemistry at the University of Washington, 2000. Tamara completed her post-doctoral research at Stanford University and Lectured at San Jose University, before entering the pharmaceutical industry in Palo Alto, CA, 2004. Tamara has remained in the industry for 20 years, working at start-up and medium cap pharma companies across multiple disciplines for example Alexza Pharmaceuticals (acquired by Ferrer), Cypress Pharmaceuticals, and Pernix Therapeutics.

<u>Robert Lewis – Chief Operating Officer and Director</u>. Robert Lewis earned his B.S. in Chemistry & Biology from Columbia College. Robert went on to work at global companies like Teva and Sigma as well as mid-tier and small pharma. Robert was an equity partner of Cypress Pharmaceutical and held the position of CSO, heading the departments of Scientific Affairs, Clinical Affairs, Regulatory Affairs, and Domestic and International Business Development. Cypress sold to a publicly traded company (Pernix) in 2012 for $102M. Additionally, Robert is an equity partner and sits on the BOD in other start-up companies in Pharma and Medical Device fields.

<u>Brian Cogley – Chief Financial Officer</u>. Brian Cogley is a senior-level financial executive with over 15 years of experience in corporate finance and accounting across a variety of industries, including life sciences, pharmaceuticals, financial services, and manufacturing.

<u>Bruce A. Cassidy, Independent Director.</u> Bruce Cassidy joined our Board of Directors in August of 2024. Since 2017 he has been the Chairman of the Board of Sarasota Green Group. He currently serves on other boards for various companies, including as chairman of the board of each of Arboreta Healthcare (August 2020), KeyStar Corporation (d/b/a Zensports) (August 2022), Loop Media, Inc. (Board Member February 2020 and Chairman January 2021) and as a member of the board of Oragenics, Inc. (October 2023). Mr. Cassidy was chosen to serve as a member of our Board of Directors due to his extensive leadership and business experience and as a CEO of a large company, as well as his service on other boards of directors.

<u>Martin Lewis, Director.</u> Mr. Lewis joined our Board of Directors in August of 2024. Mr. Lewis has over 40 years of experience in Accounting and is a Certified Public Accountant. Mr. Lewis joined his current firm, Lewis, Kaufman & Co., P.C., in 1983. Mr. Lewis has been very active in the professional accounting field, having active memberships for a number of years with the American Institute of C.P.A.s, Texas Society of C.P.A.s, National Society of Accountants for Cooperatives and the Management of Accounting Practice - West Texas Chapter.

<u>REPRESENTATIONS AND AGREEMENTS OF THE PARTIES</u>

<u>Company Representations.</u> The Company is a duly formed and valid entity existing under Florida law. The Company has all right and title to enter into this Agreement without condition or reservation. The Company has the full legal right and authority to issue the Shares purchased by Purchaser hereunder.

<u>Purchaser Representations.</u> Purchaser represents that he or she has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment and has so evaluated the merits and risks of such investment. Purchaser has been afforded full and complete opportunity to receive and review all business and financial information regarding the Company and its business and is satisfied as to the same. Purchaser is able to bear the economic risk of this investment and, at the present time, is able to afford a complete loss of such investment. Purchaser has had the opportunity to seek the advice of legal or financial advisers regarding this investment and has carefully reviewed all Risk Factors associated with this highly speculative and risky investment.

<u>RISK FACTORS</u>

The purchase of Shares is subject to a number of significant risks in the Company or businesses in which the Company operates. The following risk factors should be carefully considered.

**Investments in small businesses and start-up companies are often risky.**

Small businesses may depend heavily upon a single customer, supplier, or employee whose departure would seriously damage the Company's profitability. The demand for the Company's product may be seasonal or be impacted by the overall economy, or the Company could face other risks that are specific to its industry or type of business. The Company may also have difficulty competing against larger companies who can negotiate for better prices from suppliers, produce goods and services on a large scale more economically, or take advantage of bigger marketing budgets. Furthermore, a small business could face risks from lawsuits, governmental regulations, and other potential impediments to growth.

**The Company may need additional capital, which may not be available.**

The Company may require funds in excess of its existing cash resources to fund operating deficits, develop new products or services, establish, and expand its marketing capabilities, and finance general and administrative activities. Due to market conditions at the time the Company may need additional funding, or due to its financial condition at that time, it is possible that the Company will be unable to obtain additional funding as and when it needs it and that could significantly affect the success of the Company.

**The Company's management has broad discretion in how the Company use the net proceeds of an offering.**

The Company's management will have considerable discretion over the use of proceeds from their offering. You may not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.

**The Company faces significant competition and operates in a highly regulated industry.**

The Company operates in the areas of bio-technology products and services, which is a highly competitive industry. There is substantial competition in the industry and many of the competitors are larger companies with deeper resources than the Company. Therefore, the Company will face stiff competition as it seeks to grow and execute its business plan. In addition, the Company operates in a highly regulated industry and as a result can incur significant costs and regulatory hurdles in bringing its products to market. Competitors may be better financed and able to overcome these regulatory hurdles and as such the Company may be at a disadvantage in the marketplace as a result.

**The Company may not be able to manage its potential growth.**

For the Company to succeed, it needs to experience significant expansion. There can be no assurance that it will achieve this expansion. This expansion, if accomplished, may place a significant strain on the Company's management, operational and financial resources. To manage any material growth, the Company will be required to implement operational and financial systems, procedures and controls. It will also be required to expand its finance, administrative and operations staff. There can be no assurance that the Company's current and planned personnel, systems, procedures and controls will be adequate to support its future operations at any increased level. The Company's failure to manage growth effectively could have a material adverse effect on its business, results of operations and financial condition.

**The Company's success relies on market acceptance.**

While the Company believes that there will be significant customer demand for its products/services, there is no assurance that there will be broad market acceptance of the Company's product offerings. In such event, there may be a material adverse effect on the Company's results of operations and financial condition, and the Company may not be able to achieve its business goals.

**We have a limited operating history, which may make it difficult for investors to predict future performance based on current operations.**

We have a limited operating history upon which investors may base an evaluation of our potential future performance. In particular, our limited staff and operating history means that there is a high degree of uncertainty regarding our ability to (i) develop and commercialize our technologies and proposed products (ii) obtain regulatory approval to commence the marketing of our products, (iii) manage growth, (iv) achieve market acceptance or insurance reimbursement for any of our proposed products, if successfully developed, or (v) respond to competition. As a result, there can be no assurance that we will be able to develop or maintain consistent revenue sources, or that our operations will be profitable and/or generate positive cash flows.

Any forecasts we make about our operations may prove to be inaccurate. We must, among other things, determine appropriate risks, rewards, and level of investment in our product lines, respond to economic and market variables outside of our control, respond to competitive developments and continue to attract, retain, and motivate qualified employees. There can be no assurance that we will be successful in meeting these challenges and addressing such risks and the failure to do so could have a materially adverse effect on our business, results of operations, and financial condition. Our prospects must be considered in light of the risks, expenses, and difficulties frequently encountered by companies in the early stage of development. As a result of these risks, challenges, and uncertainties, the value of your investment could be significantly reduced or completely lost.

**If we are unable to successfully identify, develop, and commercialize any product candidates, or experience significant delays in doing so, our business, financial condition, and results of operations will be materially adversely affected.**

Our ability to generate revenue from sales of any of our product candidates, which we do not expect to occur for at least the next several years, if ever, will depend heavily on the timely and successful identification, development, regulatory approval, and eventual commercialization of any such product candidates, which may never occur. To date, we have not generated revenue from sales of any products, and we may never be able to develop, obtain regulatory approval for, or commercialize a marketable product. Before we generate any revenue from product sales of any of our current or potential future product candidates, we will need to manage preclinical, clinical, and manufacturing activities, including undertaking significant clinical development, obtain regulatory approval in multiple jurisdictions, establish manufacturing supply, including commercial manufacturing supply, and build a commercial organization, which will require substantial investment and significant marketing efforts. We may never receive regulatory approval for any of our product candidates, which would prevent us from marketing, promoting, or selling any of our product candidates and generating revenue.

**Our success depends on our ability to protect our intellectual property rights and proprietary technologies, and we may not be able to protect our intellectual property rights throughout the world.**

Patent rights are generally national or regional rights. The filing, prosecution, maintenance, and defense of patent rights on our platform technologies and product candidates worldwide would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may have a different scope and strength than do those in the United States. In addition, the laws of some foreign countries, particularly certain developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our intellectual property rights in all countries outside the United States or from making, using, selling, or importing products made using our intellectual property rights in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained intellectual property rights, including patent protection, to develop their own products and may also export otherwise infringing products to territories where we have intellectual property rights, including patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products and our patent or other intellectual property rights may not be effective or adequate to prevent them from competing.

**The Company's founders, directors and executive officers own or control a majority of the Company.**

Additionally, the holdings of the Company's directors and executive officers may increase in the future upon vesting or other maturation of exercise rights under any of the options or warrants they may hold or in the future be granted or if they otherwise acquire additional interest in the Company. The interests of such persons may differ from the interests of the Company's other stockholders, including purchasers of securities in the offering. As a result, in addition to their board seats and offices, such persons will have significant influence over and control all corporate actions requiring stockholder approval, irrespective of how the Company's other stockholders, including purchasers in the offering, may vote.

**The Company may not be able to accomplish its public listing, and a market may not develop for the Shares.**

The Company is planning to become publicly listed within 12 months from the date hereof. However, there is no assurance that such public listing will ever occur or that a market will ever develop for the sale of the Shares in either event.

<u>MISCELLANEOUS</u>

<u>Entire Agreement</u>. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Agreement.

<u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on date of transmission if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

<u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

<u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. Neither party may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party.

<u>No Third-Party Beneficiaries</u>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by any other Person.

<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Florida, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this shall be commenced exclusively in the state and federal courts sitting in Volusia County, Florida.

<u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

<u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a ".pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or ".pdf" signature page is an original thereof.

<u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

**<u>WAIVER OF JURY TRIAL</u>. <u>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</u>**

IN WITNESS WHEREOF, the parties hereto have caused this Subscription Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

---

| | |
|:---|:---|
| **JABEZ BIOSCIENCES, INC.** | **JABEZ BIOSCIENCES, INC.** |
| By: | /s/ Tamara Jovonovich |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tamara Jovonovich, President and CEO | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tamara Jovonovich, President and CEO |

---

**PURCHASER(S) / AUTHORIZED SIGNER**

---

| | |
|:---|:---|
| Company Name: | MedTek, LLC |
| Signature: | /s/ Jim Bullard |
| Print Name: | Jim Bullard |
|  | First Last |
| Title: | Manager |
| SSN# or FEIN: |  |
| Street Address: | 2308 W 5<sup>th</sup> Street |
| City: | Plainview, TX 79072 |
| Phone: | 806-777- 1158 |
| Email: | jbullard1@aol.com |

---

**REGISTRATION TYPE:** (Select only one)

☐ Individual ☒ Company ☐ Joint Tenants ☐ Custodian IRA Account F/B/O (fill in below)

☐ Trust / Trustee: ________________________________________________ Trust Date: ______________________

**IF CUSTODIAL IRA, PLEASE COMPLETE**

Authorized Signer: _______________________________________________________________________________

Registration Name: _______________________________________________________________________________

Tax ID #: ___________________________________________ Phone #: ____________________________________

Address: _______________________________________________________________________________________

## Ex1Sa-6

**Exhibit 6.12**

**JABEZ BIOSCIENCES, INC.**

**$3,000,000 PRIVATE OFFERING OF COMMON STOCK**

**<u>OFFERING MEMORANDUM AND SUBSCRIPTION AGREEMENT</u>**

This Subscription Agreement (this "<u>Agreement</u>") is dated as of <u>March 25, 2025</u> between Jabez Biosciences, Inc., a Florida corporation ("Jabez" or the "<u>Company</u>") and MedTek, LLC, a Florida limited liability company, ("<u>Purchaser</u>").

WHEREAS, the Company is in the process of selling up to $3,000,000 of Common Stock to certain accredited and/or sophisticated investors, with a minimum purchase amount of $500.

WHEREAS, the Common Stock is being sold to select accredited and non-accredited but sophisticated investors in a private offering under Regulation D, Rule 506(b) as of August 02, 2024; and

WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to Purchaser, and Purchaser desires to purchase from the Company, certain of those Common Stock of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

<u>THE OFFERING</u>

Terms of Offering. The Company is offering Class "A" Common Stock at $1 per share.

<u>Common Stock</u>. The Company is selling Class "A" Common Stock (the "Shares"), in advance of its planned public markets listing, at a price of $1 per share. The Company is planning to undertake a public listing on either a national exchange or the OTCQB or OTCQX within 12 months from the date of this offering. The Shares, once issued, will be restricted for a minimum of 6 months under applicable federal securities laws.

<u>PURCHASE AND SALE</u>

<u>Purchase Amount</u>. the Company agrees to sell, and Purchaser agrees to purchase:

a total of <u>100,000</u> Shares from Company at $1 per share

for a total purchase amount of $<u>100,000</u>.

Purchaser shall deliver to the Company, via wire transfer or a certified check, immediately available funds equal to such Purchaser's Purchase Amount as set forth herein.

<u>THE COMPANY</u>

Jabez Biosciences is a Clinical Stage Biotechnology company developing liquid and solid tumor therapies. The company's lead technology is a dihydroorotate dehydrogenase (DHODH) small molecule inhibitor. This proprietary small molecule is easily synthesized, encapsulated for oral dosing, and stores at room temperature. Strong pre-clinical data suggests that the Jabez molecule may be a safe and effective therapeutic in humans for a number of solid and liquid tumors, allowing for an Investigational New Drug application. Jabez's novel DHODH compound was created and developed by world class scientists at The Ohio State University James Cancer Hospital and Solove Research Institute . The drug inhibits tumor cell growth and survival by not allowing cells to repair and multiply. This treatment is considered a *targeted* therapy (unlike a chemotherapy) because it only effects proliferative diseases where the diseased cells need to grow at accelerated rates, such as cancer. The way normal cells repair and multiply is unaffected. The drug is Phase I ready with anticipated IND filing in June 2024 and anticipated study start in September/October 2024.

The DHODH inhibitor is anticipated to be a First Line Treatment, for several solid and liquid tumor types, many qualifying for FDA fast track, priority review, and orphan status, creating "first in the que" reviews from the FDA and shorter times to approval. The DHODH inhibitor class has become an increasingly popular inhibitor in recent years. The FDA approved multiple DHODH drug programs such as Sanofi's Arava®, indicated for rheumatoid arthritis, and Aubagio® indicated for multiple sclerosis.

The safety and efficacy of DHODH class is well known in the oncology space for blocking cell cycle progression and inducing apoptosis, which has led companies like Johnson & Johnson Innovative Medicine (J&J, formerly Janssen) to invest in their own DHODH program for Acute Myeloid Leukemia (AML). J&J's multi-year investment has no doubt stirred the interest of Big Pharma in this class of drug and should help validate Jabez' own program while increasing its intrinsic value. Interest in Jabez by other Big Pharma companies looking to expand their small molecule platforms may have some comfort level in the future because of J&J's program.

**<u>Officers and Directors</u>**

<u>Tamara Jovonovich – President, Chief Executive Officer and Director</u>. Tamara Jovonovich received a B.S. in Chemistry and a B.S.in Fine Arts from the University of Central Florida, 1996, and went on to earn her PhD. in Biophysical Chemistry at the University of Washington, 2000. Tamara completed her post-doctoral research at Stanford University and Lectured at San Jose University, before entering the pharmaceutical industry in Palo Alto, CA, 2004. Tamara has remained in the industry for 20 years, working at start-up and medium cap pharma companies across multiple disciplines for example Alexza Pharmaceuticals (acquired by Ferrer), Cypress Pharmaceuticals, and Pernix Therapeutics.

<u>Robert Lewis – Chief Operating Officer and Director</u>. Robert Lewis earned his B.S. in Chemistry & Biology from Columbia College. Robert went on to work at global companies like Teva and Sigma as well as mid-tier and small pharma. Robert was an equity partner of Cypress Pharmaceutical and held the position of CSO, heading the departments of Scientific Affairs, Clinical Affairs, Regulatory Affairs, and Domestic and International Business Development. Cypress sold to a publicly traded company (Pernix) in 2012 for $102M. Additionally, Robert is an equity partner and sits on the BOD in other start-up companies in Pharma and Medical Device fields.

<u>Brian Cogley – Chief Financial Officer</u>. Brian Cogley is a senior-level financial executive with over 15 years of experience in corporate finance and accounting across a variety of industries, including life sciences, pharmaceuticals, financial services, and manufacturing.

<u>Bruce A. Cassidy, Independent Director.</u> Bruce Cassidy joined our Board of Directors in August of 2024. Since 2017 he has been the Chairman of the Board of Sarasota Green Group. He currently serves on other boards for various companies, including as chairman of the board of each of Arboreta Healthcare (August 2020), KeyStar Corporation (d/b/a Zensports) (August 2022), Loop Media, Inc. (Board Member February 2020 and Chairman January 2021) and as a member of the board of Oragenics, Inc. (October 2023). Mr. Cassidy was chosen to serve as a member of our Board of Directors due to his extensive leadership and business experience and as a CEO of a large company, as well as his service on other boards of directors.

<u>Martin Lewis, Director.</u> Mr. Lewis joined our Board of Directors in August of 2024. Mr. Lewis has over 40 years of experience in Accounting and is a Certified Public Accountant. Mr. Lewis joined his current firm, Lewis, Kaufman & Co., P.C., in 1983. Mr. Lewis has been very active in the professional accounting field, having active memberships for a number of years with the American Institute of C.P.A.s, Texas Society of C.P.A.s, National Society of Accountants for Cooperatives and the Management of Accounting Practice - West Texas Chapter.

<u>REPRESENTATIONS AND AGREEMENTS OF THE PARTIES</u>

<u>Company Representations.</u> The Company is a duly formed and valid entity existing under Florida law. The Company has all right and title to enter into this Agreement without condition or reservation. The Company has the full legal right and authority to issue the Shares purchased by Purchaser hereunder.

<u>Purchaser Representations.</u> Purchaser represents that he or she has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment and has so evaluated the merits and risks of such investment. Purchaser has been afforded full and complete opportunity to receive and review all business and financial information regarding the Company and its business and is satisfied as to the same. Purchaser is able to bear the economic risk of this investment and, at the present time, is able to afford a complete loss of such investment. Purchaser has had the opportunity to seek the advice of legal or financial advisers regarding this investment and has carefully reviewed all Risk Factors associated with this highly speculative and risky investment.

<u>RISK FACTORS</u>

The purchase of Shares is subject to a number of significant risks in the Company or businesses in which the Company operates. The following risk factors should be carefully considered.

**Investments in small businesses and start-up companies are often risky.**

Small businesses may depend heavily upon a single customer, supplier, or employee whose departure would seriously damage the Company's profitability. The demand for the Company's product may be seasonal or be impacted by the overall economy, or the Company could face other risks that are specific to its industry or type of business. The Company may also have difficulty competing against larger companies who can negotiate for better prices from suppliers, produce goods and services on a large scale more economically, or take advantage of bigger marketing budgets. Furthermore, a small business could face risks from lawsuits, governmental regulations, and other potential impediments to growth.

**The Company may need additional capital, which may not be available.**

The Company may require funds in excess of its existing cash resources to fund operating deficits, develop new products or services, establish, and expand its marketing capabilities, and finance general and administrative activities. Due to market conditions at the time the Company may need additional funding, or due to its financial condition at that time, it is possible that the Company will be unable to obtain additional funding as and when it needs it and that could significantly affect the success of the Company.

**The Company's management has broad discretion in how the Company use the net proceeds of an offering.**

The Company's management will have considerable discretion over the use of proceeds from their offering. You may not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.

**The Company faces significant competition and operates in a highly regulated industry.**

The Company operates in the areas of bio-technology products and services, which is a highly competitive industry. There is substantial competition in the industry and many of the competitors are larger companies with deeper resources than the Company. Therefore, the Company will face stiff competition as it seeks to grow and execute its business plan. In addition, the Company operates in a highly regulated industry and as a result can incur significant costs and regulatory hurdles in bringing its products to market. Competitors may be better financed and able to overcome these regulatory hurdles and as such the Company may be at a disadvantage in the marketplace as a result.

**The Company may not be able to manage its potential growth.**

For the Company to succeed, it needs to experience significant expansion. There can be no assurance that it will achieve this expansion. This expansion, if accomplished, may place a significant strain on the Company's management, operational and financial resources. To manage any material growth, the Company will be required to implement operational and financial systems, procedures and controls. It will also be required to expand its finance, administrative and operations staff. There can be no assurance that the Company's current and planned personnel, systems, procedures and controls will be adequate to support its future operations at any increased level. The Company's failure to manage growth effectively could have a material adverse effect on its business, results of operations and financial condition.

**The Company's success relies on market acceptance.**

While the Company believes that there will be significant customer demand for its products/services, there is no assurance that there will be broad market acceptance of the Company's product offerings. In such event, there may be a material adverse effect on the Company's results of operations and financial condition, and the Company may not be able to achieve its business goals.

**We have a limited operating history, which may make it difficult for investors to predict future performance based on current operations.**

We have a limited operating history upon which investors may base an evaluation of our potential future performance. In particular, our limited staff and operating history means that there is a high degree of uncertainty regarding our ability to (i) develop and commercialize our technologies and proposed products (ii) obtain regulatory approval to commence the marketing of our products, (iii) manage growth,

(iv) achieve market acceptance or insurance reimbursement for any of our proposed products, if successfully developed, or (v) respond to competition. As a result, there can be no assurance that we will be able to develop or maintain consistent revenue sources, or that our operations will be profitable and/or generate positive cash flows.

Any forecasts we make about our operations may prove to be inaccurate. We must, among other things, determine appropriate risks, rewards, and level of investment in our product lines, respond to economic and market variables outside of our control, respond to competitive developments and continue to attract, retain, and motivate qualified employees. There can be no assurance that we will be successful in meeting these challenges and addressing such risks and the failure to do so could have a materially adverse effect on our business, results of operations, and financial condition. Our prospects must be considered in light of the risks, expenses, and difficulties frequently encountered by companies in the early stage of development. As a result of these risks, challenges, and uncertainties, the value of your investment could be significantly reduced or completely lost.

**If we are unable to successfully identify, develop, and commercialize any product candidates, or experience significant delays in doing so, our business, financial condition, and results of operations will be materially adversely affected.**

Our ability to generate revenue from sales of any of our product candidates, which we do not expect to occur for at least the next several years, if ever, will depend heavily on the timely and successful identification, development, regulatory approval, and eventual commercialization of any such product candidates, which may never occur. To date, we have not generated revenue from sales of any products, and we may never be able to develop, obtain regulatory approval for, or commercialize a marketable product. Before we generate any revenue from product sales of any of our current or potential future product candidates, we will need to manage preclinical, clinical, and manufacturing activities, including undertaking significant clinical development, obtain regulatory approval in multiple jurisdictions, establish manufacturing supply, including commercial manufacturing supply, and build a commercial organization, which will require substantial investment and significant marketing efforts. We may never receive regulatory approval for any of our product candidates, which would prevent us from marketing, promoting, or selling any of our product candidates and generating revenue.

**Our success depends on our ability to protect our intellectual property rights and proprietary technologies, and we may not be able to protect our intellectual property rights throughout the world.**

Patent rights are generally national or regional rights. The filing, prosecution, maintenance, and defense of patent rights on our platform technologies and product candidates worldwide would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may have a different scope and strength than do those in the United States. In addition, the laws of some foreign countries, particularly certain developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our intellectual property rights in all countries outside the United States or from making, using, selling, or importing products made using our intellectual property rights in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained intellectual property rights, including patent protection, to develop their own products and may also export otherwise infringing products to territories where we have intellectual property rights, including patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products and our patent or other intellectual property rights may not be effective or adequate to prevent them from competing.

**The Company's founders, directors and executive officers own or control a majority of the Company.**

Additionally, the holdings of the Company's directors and executive officers may increase in the future upon vesting or other maturation of exercise rights under any of the options or warrants they may hold or in the future be granted or if they otherwise acquire additional interest in the Company. The interests of such persons may differ from the interests of the Company's other stockholders, including purchasers of securities in the offering. As a result, in addition to their board seats and offices, such persons will have significant influence over and control all corporate actions requiring stockholder approval, irrespective of how the Company's other stockholders, including purchasers in the offering, may vote.

**The Company may not be able to accomplish its public listing, and a market may not develop for the Shares.**

The Company is planning to become publicly listed within 12 months from the date hereof. However, there is no assurance that such public listing will ever occur or that a market will ever develop for the sale of the Shares in either event.

<u>MISCELLANEOUS</u>

<u>Entire Agreement</u>. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Agreement.

<u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on date of transmission if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

<u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

<u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. Neither party may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party.

<u>No Third-Party Beneficiaries</u>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by any other Person.

<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Florida, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this shall be commenced exclusively in the state and federal courts sitting in Volusia County, Florida.

<u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

<u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a ".pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or ".pdf" signature page is an original thereof.

<u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

**<u>WAIVER OF JURY TRIAL</u>. <u>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</u>**

IN WITNESS WHEREOF, the parties hereto have caused this Subscription Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

---

| | |
|:---|:---|
| **JABEZ BIOSCIENCES, INC.** | **JABEZ BIOSCIENCES, INC.** |
| By: | /s/ Tamara Jovonovich |
|  | Tamara Jovonovich, President and CEO |

---

**PURCHASER(S) / AUTHORIZED SIGNER**

---

| | |
|:---|:---|
| Company Name: | MEDTEK, LLC |
| Signature: | /s/ Jim Bullard |
| Print Name: | Jim Bullard |
|  | First Last |
| Title: | Manager |
| SSN# or FEIN: |  |
| Street Address: | 2308 W 5<sup>th</sup> Street |
| City: | Plainview, TX 79072 |
| Phone: | 806-777-1158 |
| Email: | jbullard1@aol.com |

---

**REGISTRATION TYPE:** (Select only one)

☐ Individual ☒ Company ☐ Joint Tenants ☐ Custodian IRA Account F/B/O (fill in below)

☐ Trust / Trustee: ________________________________________________ Trust Date: ______________________

**IF CUSTODIAL IRA, PLEASE COMPLETE**

Authorized Signer: _______________________________________________________________________________

Registration Name: _______________________________________________________________________________

Tax ID #: ___________________________________________ Phone #: ____________________________________

Address: _______________________________________________________________________________________

## Ex1Sa-6

**Exhibit 6.13**

**JABEZ BIOSCIENCES, INC.**

**$3,000,000 PRIVATE OFFERING OF COMMON STOCK**

**<u>OFFERING MEMORANDUM AND SUBSCRIPTION AGREEMENT</u>**

This Subscription Agreement (this "<u>Agreement</u>") is dated as of <u>April 28, 2025</u> between Jabez Biosciences, Inc., a Florida corporation ("Jabez" or the "<u>Company</u>") and MedTek, LLC, a Florida limited liability company, ("<u>Purchaser</u>").

WHEREAS, the Company is in the process of selling up to $3,000,000 of Common Stock to certain accredited and/or sophisticated investors, with a minimum purchase amount of $500.

WHEREAS, the Common Stock is being sold to select accredited and non-accredited but sophisticated investors in a private offering under Regulation D, Rule 506(b) as of August 02, 2024; and

WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to Purchaser, and Purchaser desires to purchase from the Company, certain of those Common Stock of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

<u>THE OFFERING</u>

Terms of Offering. The Company is offering Class "A" Common Stock at $1 per share.

<u>Common Stock</u>. The Company is selling Class "A" Common Stock (the "Shares"), in advance of its planned public markets listing, at a price of $1 per share. The Company is planning to undertake a public listing on either a national exchange or the OTCQB or OTCQX within 12 months from the date of this offering. The Shares, once issued, will be restricted for a minimum of 6 months under applicable federal securities laws.

<u>PURCHASE AND SALE</u>

<u>Purchase Amount</u>. the Company agrees to sell, and Purchaser agrees to purchase:

a total of <u>100,000</u> Shares from Company at $1 per share

for a total purchase amount of $<u>100,000</u>.

Purchaser shall deliver to the Company, via wire transfer or a certified check, immediately available funds equal to such Purchaser's Purchase Amount as set forth herein.

<u>THE COMPANY</u>

Jabez Biosciences is a Clinical Stage Biotechnology company developing liquid and solid tumor therapies. The company's lead technology is a dihydroorotate dehydrogenase (DHODH) small molecule inhibitor. This proprietary small molecule is easily synthesized, encapsulated for oral dosing, and stores at room temperature. Strong pre-clinical data suggests that the Jabez molecule may be a safe and effective therapeutic in humans for a number of solid and liquid tumors, allowing for an Investigational New Drug application. Jabez's novel DHODH compound was created and developed by world class scientists at The Ohio State University James Cancer Hospital and Solove Research Institute . The drug inhibits tumor cell growth and survival by not allowing cells to repair and multiply. This treatment is considered a *targeted* therapy (unlike a chemotherapy) because it only effects proliferative diseases where the diseased cells need to grow at accelerated rates, such as cancer. The way normal cells repair and multiply is unaffected. The drug is Phase I ready with anticipated IND filing in June 2024 and anticipated study start in September/October 2024.

The DHODH inhibitor is anticipated to be a First Line Treatment, for several solid and liquid tumor types, many qualifying for FDA fast track, priority review, and orphan status, creating "first in the que" reviews from the FDA and shorter times to approval. The DHODH inhibitor class has become an increasingly popular inhibitor in recent years. The FDA approved multiple DHODH drug programs such as Sanofi's Arava®, indicated for rheumatoid arthritis, and Aubagio® indicated for multiple sclerosis.

The safety and efficacy of DHODH class is well known in the oncology space for blocking cell cycle progression and inducing apoptosis, which has led companies like Johnson & Johnson Innovative Medicine (J&J, formerly Janssen) to invest in their own DHODH program for Acute Myeloid Leukemia (AML). J&J's multi-year investment has no doubt stirred the interest of Big Pharma in this class of drug and should help validate Jabez' own program while increasing its intrinsic value. Interest in Jabez by other Big Pharma companies looking to expand their small molecule platforms may have some comfort level in the future because of J&J's program.

**<u>Officers and Directors</u>**

<u>Tamara Jovonovich – President, Chief Executive Officer and Director</u>. Tamara Jovonovich received a B.S. in Chemistry and a B.S.in Fine Arts from the University of Central Florida, 1996, and went on to earn her PhD. in Biophysical Chemistry at the University of Washington, 2000. Tamara completed her post-doctoral research at Stanford University and Lectured at San Jose University, before entering the pharmaceutical industry in Palo Alto, CA, 2004. Tamara has remained in the industry for 20 years, working at start-up and medium cap pharma companies across multiple disciplines for example Alexza Pharmaceuticals (acquired by Ferrer), Cypress Pharmaceuticals, and Pernix Therapeutics.

<u>Robert Lewis – Chief Operating Officer and Director</u>. Robert Lewis earned his B.S. in Chemistry & Biology from Columbia College. Robert went on to work at global companies like Teva and Sigma as well as mid-tier and small pharma. Robert was an equity partner of Cypress Pharmaceutical and held the position of CSO, heading the departments of Scientific Affairs, Clinical Affairs, Regulatory Affairs, and Domestic and International Business Development. Cypress sold to a publicly traded company (Pernix) in 2012 for $102M. Additionally, Robert is an equity partner and sits on the BOD in other start-up companies in Pharma and Medical Device fields.

<u>Brian Cogley – Chief Financial Officer</u>. Brian Cogley is a senior-level financial executive with over 15 years of experience in corporate finance and accounting across a variety of industries, including life sciences, pharmaceuticals, financial services, and manufacturing.

<u>Bruce A. Cassidy, Director.</u> Bruce Cassidy joined our Board of Directors in August of 2024. Since 2017 he has been the Chairman of the Board of Sarasota Green Group. He currently serves on other boards for various companies, including as chairman of the board of each of Arboreta Healthcare (August 2020), KeyStar Corporation (d/b/a Zensports) (August 2022), Loop Media, Inc. (Board Member February 2020 and Chairman January 2021) and as a member of the board of Oragenics, Inc. (October 2023). Mr. Cassidy was chosen to serve as a member of our Board of Directors due to his extensive leadership and business experience and as a CEO of a large company, as well as his service on other boards of directors.

<u>Martin Lewis, Director.</u> Mr. Lewis joined our Board of Directors in August of 2024. Mr. Lewis has over 40 years of experience in Accounting and is a Certified Public Accountant. Mr. Lewis joined his current firm, Lewis, Kaufman & Co., P.C., in 1983. Mr. Lewis has been very active in the professional accounting field, having active memberships for a number of years with the American Institute of C.P.A.s, Texas Society of C.P.A.s, National Society of Accountants for Cooperatives and the Management of Accounting Practice - West Texas Chapter.

<u>REPRESENTATIONS AND AGREEMENTS OF THE PARTIES</u>

<u>Company Representations.</u> The Company is a duly formed and valid entity existing under Florida law. The Company has all right and title to enter into this Agreement without condition or reservation. The Company has the full legal right and authority to issue the Shares purchased by Purchaser hereunder.

<u>Purchaser Representations.</u> Purchaser represents that he or she has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment and has so evaluated the merits and risks of such investment. Purchaser has been afforded full and complete opportunity to receive and review all business and financial information regarding the Company and its business and is satisfied as to the same. Purchaser is able to bear the economic risk of this investment and, at the present time, is able to afford a complete loss of such investment. Purchaser has had the opportunity to seek the advice of legal or financial advisers regarding this investment and has carefully reviewed all Risk Factors associated with this highly speculative and risky investment.

<u>RISK FACTORS</u>

The purchase of Shares is subject to a number of significant risks in the Company or businesses in which the Company operates. The following risk factors should be carefully considered.

**Investments in small businesses and start-up companies are often risky.**

Small businesses may depend heavily upon a single customer, supplier, or employee whose departure would seriously damage the Company's profitability. The demand for the Company's product may be seasonal or be impacted by the overall economy, or the Company could face other risks that are specific to its industry or type of business. The Company may also have difficulty competing against larger companies who can negotiate for better prices from suppliers, produce goods and services on a large scale more economically, or take advantage of bigger marketing budgets. Furthermore, a small business could face risks from lawsuits, governmental regulations, and other potential impediments to growth.

**The Company may need additional capital, which may not be available.**

The Company may require funds in excess of its existing cash resources to fund operating deficits, develop new products or services, establish, and expand its marketing capabilities, and finance general and administrative activities. Due to market conditions at the time the Company may need additional funding, or due to its financial condition at that time, it is possible that the Company will be unable to obtain additional funding as and when it needs it and that could significantly affect the success of the Company.

**The Company's management has broad discretion in how the Company use the net proceeds of an offering.**

The Company's management will have considerable discretion over the use of proceeds from their offering. You may not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.

**The Company faces significant competition and operates in a highly regulated industry.**

The Company operates in the areas of bio-technology products and services, which is a highly competitive industry. There is substantial competition in the industry and many of the competitors are larger companies with deeper resources than the Company. Therefore, the Company will face stiff competition as it seeks to grow and execute its business plan. In addition, the Company operates in a highly regulated industry and as a result can incur significant costs and regulatory hurdles in bringing its products to market. Competitors may be better financed and able to overcome these regulatory hurdles and as such the Company may be at a disadvantage in the marketplace as a result.

**The Company may not be able to manage its potential growth.**

For the Company to succeed, it needs to experience significant expansion. There can be no assurance that it will achieve this expansion. This expansion, if accomplished, may place a significant strain on the Company's management, operational and financial resources. To manage any material growth, the Company will be required to implement operational and financial systems, procedures and controls. It will also be required to expand its finance, administrative and operations staff. There can be no assurance that the Company's current and planned personnel, systems, procedures and controls will be adequate to support its future operations at any increased level. The Company's failure to manage growth effectively could have a material adverse effect on its business, results of operations and financial condition.

**The Company's success relies on market acceptance.**

While the Company believes that there will be significant customer demand for its products/services, there is no assurance that there will be broad market acceptance of the Company's product offerings. In such event, there may be a material adverse effect on the Company's results of operations and financial condition, and the Company may not be able to achieve its business goals.

**We have a limited operating history, which may make it difficult for investors to predict future performance based on current operations.**

We have a limited operating history upon which investors may base an evaluation of our potential future performance. In particular, our limited staff and operating history means that there is a high degree of uncertainty regarding our ability to (i) develop and commercialize our technologies and proposed products (ii) obtain regulatory approval to commence the marketing of our products, (iii) manage growth, (iv) achieve market acceptance or insurance reimbursement for any of our proposed products, if successfully developed, or (v) respond to competition. As a result, there can be no assurance that we will be able to develop or maintain consistent revenue sources, or that our operations will be profitable and/or generate positive cash flows.

Any forecasts we make about our operations may prove to be inaccurate. We must, among other things, determine appropriate risks, rewards, and level of investment in our product lines, respond to economic and market variables outside of our control, respond to competitive developments and continue to attract, retain, and motivate qualified employees. There can be no assurance that we will be successful in meeting these challenges and addressing such risks and the failure to do so could have a materially adverse effect on our business, results of operations, and financial condition. Our prospects must be considered in light of the risks, expenses, and difficulties frequently encountered by companies in the early stage of development. As a result of these risks, challenges, and uncertainties, the value of your investment could be significantly reduced or completely lost.

**If we are unable to successfully identify, develop, and commercialize any product candidates, or experience significant delays in doing so, our business, financial condition, and results of operations will be materially adversely affected.**

Our ability to generate revenue from sales of any of our product candidates, which we do not expect to occur for at least the next several years, if ever, will depend heavily on the timely and successful identification, development, regulatory approval, and eventual commercialization of any such product candidates, which may never occur. To date, we have not generated revenue from sales of any products, and we may never be able to develop, obtain regulatory approval for, or commercialize a marketable product. Before we generate any revenue from product sales of any of our current or potential future product candidates, we will need to manage preclinical, clinical, and manufacturing activities, including undertaking significant clinical development, obtain regulatory approval in multiple jurisdictions, establish manufacturing supply, including commercial manufacturing supply, and build a commercial organization, which will require substantial investment and significant marketing efforts. We may never receive regulatory approval for any of our product candidates, which would prevent us from marketing, promoting, or selling any of our product candidates and generating revenue.

**Our success depends on our ability to protect our intellectual property rights and proprietary technologies, and we may not be able to protect our intellectual property rights throughout the world.**

Patent rights are generally national or regional rights. The filing, prosecution, maintenance, and defense of patent rights on our platform technologies and product candidates worldwide would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may have a different scope and strength than do those in the United States. In addition, the laws of some foreign countries, particularly certain developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our intellectual property rights in all countries outside the United States or from making, using, selling, or importing products made using our intellectual property rights in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained intellectual property rights, including patent protection, to develop their own products and may also export otherwise infringing products to territories where we have intellectual property rights, including patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products and our patent or other intellectual property rights may not be effective or adequate to prevent them from competing.

**The Company's founders, directors and executive officers own or control a majority of the Company.**

Additionally, the holdings of the Company's directors and executive officers may increase in the future upon vesting or other maturation of exercise rights under any of the options or warrants they may hold or in the future be granted or if they otherwise acquire additional interest in the Company. The interests of such persons may differ from the interests of the Company's other stockholders, including purchasers of securities in the offering. As a result, in addition to their board seats and offices, such persons will have significant influence over and control all corporate actions requiring stockholder approval, irrespective of how the Company's other stockholders, including purchasers in the offering, may vote.

**The Company may not be able to accomplish its public listing, and a market may not develop for the Shares.**

The Company is planning to become publicly listed within 12 months from the date hereof. However, there is no assurance that such public listing will ever occur or that a market will ever develop for the sale of the Shares in either event.

<u>MISCELLANEOUS</u>

<u>Entire Agreement</u>. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Agreement.

<u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on date of transmission if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

<u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

<u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. Neither party may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party.

<u>No Third-Party Beneficiaries</u>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by any other Person.

<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Florida, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this shall be commenced exclusively in the state and federal courts sitting in Volusia County, Florida.

<u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

<u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a ".pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or ".pdf" signature page is an original thereof.

<u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

**<u>WAIVER OF JURY TRIAL</u>. <u>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</u>**

IN WITNESS WHEREOF, the parties hereto have caused this Subscription Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

---

| | |
|:---|:---|
| **JABEZ BIOSCIENCES, INC.** | **JABEZ BIOSCIENCES, INC.** |
| By: | /s/ Tamara Jovonovich |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tamara Jovonovich, President and CEO | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tamara Jovonovich, President and CEO |

---

**PURCHASER(S) / AUTHORIZED SIGNER**

---

| | |
|:---|:---|
| Company Name: | MedTek, LLC |
| Signature: | /s/ Jim Bullard |
| Print Name: | Jim Bullard |
|  | First Last |
| Title: | Manager |
| SSN# or FEIN: |  |
| Street Address: | 2308 W 5<sup>th</sup> Street |
| City: | Plainview, TX 79072 |
| Phone: | 806-777-1158 |
| Email: | jbullard1@aol.com |

---

**REGISTRATION TYPE:** (Select only one)

☐ Individual ☒ Company ☐ Joint Tenants ☐ Custodian IRA Account F/B/O (fill in below)

☐ Trust / Trustee: ________________________________________________ Trust Date: ______________________

**IF CUSTODIAL IRA, PLEASE COMPLETE**

Authorized Signer: _______________________________________________________________________________

Registration Name: _______________________________________________________________________________

Tax ID #: ___________________________________________ Phone #: ____________________________________

Address: _______________________________________________________________________________________

## Ex1Sa-6

**Exhibit 6.14**

**JABEZ BIOSCIENCES, INC.**

**$3,000,000 PRIVATE OFFERING OF COMMON STOCK**

**<u>OFFERING MEMORANDUM AND SUBSCRIPTION AGREEMENT</u>**

This Subscription Agreement (this "<u>Agreement</u>") is dated as of <u>May 28, 2025</u> between Jabez Biosciences, Inc., a Florida corporation ("Jabez" or the "<u>Company</u>") and MedTek, LLC, a Florida limited liability company, ("<u>Purchaser</u>").

WHEREAS, the Company is in the process of selling up to $3,000,000 of Common Stock to certain accredited and/or sophisticated investors, with a minimum purchase amount of $500.

WHEREAS, the Common Stock is being sold to select accredited and non-accredited but sophisticated investors in a private offering under Regulation D, Rule 506(b) as of August 02, 2024; and

WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to Purchaser, and Purchaser desires to purchase from the Company, certain of those Common Stock of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

<u>THE OFFERING</u>

Terms of Offering. The Company is offering Class "A" Common Stock at $1 per share.

<u>Common Stock</u>. The Company is selling Class "A" Common Stock (the "Shares"), in advance of its planned public markets listing, at a price of $1 per share. The Company is planning to undertake a public listing on either a national exchange or the OTCQB or OTCQX within 12 months from the date of this offering. The Shares, once issued, will be restricted for a minimum of 6 months under applicable federal securities laws.

<u>PURCHASE AND SALE</u>

<u>Purchase Amount</u>. the Company agrees to sell, and Purchaser agrees to purchase:

a total of <u>100,000</u> Shares from Company at $1 per share

for a total purchase amount of $<u>100,000</u>.

Purchaser shall deliver to the Company, via wire transfer or a certified check, immediately available funds equal to such Purchaser's Purchase Amount as set forth herein.

<u>THE COMPANY</u>

Jabez Biosciences is a Clinical Stage Biotechnology company developing liquid and solid tumor therapies. The company's lead technology is a dihydroorotate dehydrogenase (DHODH) small molecule inhibitor. This proprietary small molecule is easily synthesized, encapsulated for oral dosing, and stores at room temperature. Strong pre-clinical data suggests that the Jabez molecule may be a safe and effective therapeutic in humans for a number of solid and liquid tumors, allowing for an Investigational New Drug application. Jabez's novel DHODH compound was created and developed by world class scientists at The Ohio State University James Cancer Hospital and Solove Research Institute . The drug inhibits tumor cell growth and survival by not allowing cells to repair and multiply. This treatment is considered a *targeted* therapy (unlike a chemotherapy) because it only effects proliferative diseases where the diseased cells need to grow at accelerated rates, such as cancer. The way normal cells repair and multiply is unaffected. The drug is Phase I ready with anticipated IND filing in June 2024 and anticipated study start in September/October 2024.

The DHODH inhibitor is anticipated to be a First Line Treatment, for several solid and liquid tumor types, many qualifying for FDA fast track, priority review, and orphan status, creating "first in the que" reviews from the FDA and shorter times to approval. The DHODH inhibitor class has become an increasingly popular inhibitor in recent years. The FDA approved multiple DHODH drug programs such as Sanofi's Arava®, indicated for rheumatoid arthritis, and Aubagio® indicated for multiple sclerosis.

The safety and efficacy of DHODH class is well known in the oncology space for blocking cell cycle progression and inducing apoptosis, which has led companies like Johnson & Johnson Innovative Medicine (J&J, formerly Janssen) to invest in their own DHODH program for Acute Myeloid Leukemia (AML). J&J's multi-year investment has no doubt stirred the interest of Big Pharma in this class of drug and should help validate Jabez' own program while increasing its intrinsic value. Interest in Jabez by other Big Pharma companies looking to expand their small molecule platforms may have some comfort level in the future because of J&J's program.

**<u>Officers and Directors</u>**

<u>Tamara Jovonovich – President, Chief Executive Officer and Director</u>. Tamara Jovonovich received a B.S. in Chemistry and a B.S.in Fine Arts from the University of Central Florida, 1996, and went on to earn her PhD. in Biophysical Chemistry at the University of Washington, 2000. Tamara completed her post-doctoral research at Stanford University and Lectured at San Jose University, before entering the pharmaceutical industry in Palo Alto, CA, 2004. Tamara has remained in the industry for 20 years, working at start-up and medium cap pharma companies across multiple disciplines for example Alexza Pharmaceuticals (acquired by Ferrer), Cypress Pharmaceuticals, and Pernix Therapeutics.

<u>Robert Lewis – Chief Operating Officer and Director</u>. Robert Lewis earned his B.S. in Chemistry & Biology from Columbia College. Robert went on to work at global companies like Teva and Sigma as well as mid-tier and small pharma. Robert was an equity partner of Cypress Pharmaceutical and held the position of CSO, heading the departments of Scientific Affairs, Clinical Affairs, Regulatory Affairs, and Domestic and International Business Development. Cypress sold to a publicly traded company (Pernix) in 2012 for $102M. Additionally, Robert is an equity partner and sits on the BOD in other start-up companies in Pharma and Medical Device fields.

<u>Brian Cogley – Chief Financial Officer</u>. Brian Cogley is a senior-level financial executive with over 15 years of experience in corporate finance and accounting across a variety of industries, including life sciences, pharmaceuticals, financial services, and manufacturing.

<u>Bruce A. Cassidy, Director.</u> Bruce Cassidy joined our Board of Directors in August of 2024. Since 2017 he has been the Chairman of the Board of Sarasota Green Group. He currently serves on other boards for various companies, including as chairman of the board of each of Arboreta Healthcare (August 2020), KeyStar Corporation (d/b/a Zensports) (August 2022), Loop Media, Inc. (Board Member February 2020 and Chairman January 2021) and as a member of the board of Oragenics, Inc. (October 2023). Mr. Cassidy was chosen to serve as a member of our Board of Directors due to his extensive leadership and business experience and as a CEO of a large company, as well as his service on other boards of directors.

<u>Martin Lewis, Director.</u> Mr. Lewis joined our Board of Directors in August of 2024. Mr. Lewis has over 40 years of experience in Accounting and is a Certified Public Accountant. Mr. Lewis joined his current firm, Lewis, Kaufman & Co., P.C., in 1983. Mr. Lewis has been very active in the professional accounting field, having active memberships for a number of years with the American Institute of C.P.A.s, Texas Society of C.P.A.s, National Society of Accountants for Cooperatives and the Management of Accounting Practice - West Texas Chapter.

<u>REPRESENTATIONS AND AGREEMENTS OF THE PARTIES</u>

<u>Company Representations.</u> The Company is a duly formed and valid entity existing under Florida law. The Company has all right and title to enter into this Agreement without condition or reservation. The Company has the full legal right and authority to issue the Shares purchased by Purchaser hereunder.

<u>Purchaser Representations.</u> Purchaser represents that he or she has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment and has so evaluated the merits and risks of such investment. Purchaser has been afforded full and complete opportunity to receive and review all business and financial information regarding the Company and its business and is satisfied as to the same. Purchaser is able to bear the economic risk of this investment and, at the present time, is able to afford a complete loss of such investment. Purchaser has had the opportunity to seek the advice of legal or financial advisers regarding this investment and has carefully reviewed all Risk Factors associated with this highly speculative and risky investment.

<u>RISK FACTORS</u>

The purchase of Shares is subject to a number of significant risks in the Company or businesses in which the Company operates. The following risk factors should be carefully considered.

**Investments in small businesses and start-up companies are often risky.**

Small businesses may depend heavily upon a single customer, supplier, or employee whose departure would seriously damage the Company's profitability. The demand for the Company's product may be seasonal or be impacted by the overall economy, or the Company could face other risks that are specific to its industry or type of business. The Company may also have difficulty competing against larger companies who can negotiate for better prices from suppliers, produce goods and services on a large scale more economically, or take advantage of bigger marketing budgets. Furthermore, a small business could face risks from lawsuits, governmental regulations, and other potential impediments to growth.

**The Company may need additional capital, which may not be available.**

The Company may require funds in excess of its existing cash resources to fund operating deficits, develop new products or services, establish, and expand its marketing capabilities, and finance general and administrative activities. Due to market conditions at the time the Company may need additional funding, or due to its financial condition at that time, it is possible that the Company will be unable to obtain additional funding as and when it needs it and that could significantly affect the success of the Company.

**The Company's management has broad discretion in how the Company use the net proceeds of an offering.**

The Company's management will have considerable discretion over the use of proceeds from their offering. You may not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.

**The Company faces significant competition and operates in a highly regulated industry.**

The Company operates in the areas of bio-technology products and services, which is a highly competitive industry. There is substantial competition in the industry and many of the competitors are larger companies with deeper resources than the Company. Therefore, the Company will face stiff competition as it seeks to grow and execute its business plan. In addition, the Company operates in a highly regulated industry and as a result can incur significant costs and regulatory hurdles in bringing its products to market. Competitors may be better financed and able to overcome these regulatory hurdles and as such the Company may be at a disadvantage in the marketplace as a result.

**The Company may not be able to manage its potential growth.**

For the Company to succeed, it needs to experience significant expansion. There can be no assurance that it will achieve this expansion. This expansion, if accomplished, may place a significant strain on the Company's management, operational and financial resources. To manage any material growth, the Company will be required to implement operational and financial systems, procedures and controls. It will also be required to expand its finance, administrative and operations staff. There can be no assurance that the Company's current and planned personnel, systems, procedures and controls will be adequate to support its future operations at any increased level. The Company's failure to manage growth effectively could have a material adverse effect on its business, results of operations and financial condition.

**The Company's success relies on market acceptance.**

While the Company believes that there will be significant customer demand for its products/services, there is no assurance that there will be broad market acceptance of the Company's product offerings. In such event, there may be a material adverse effect on the Company's results of operations and financial condition, and the Company may not be able to achieve its business goals.

**We have a limited operating history, which may make it difficult for investors to predict future performance based on current operations.**

We have a limited operating history upon which investors may base an evaluation of our potential future performance. In particular, our limited staff and operating history means that there is a high degree of uncertainty regarding our ability to (i) develop and commercialize our technologies and proposed products (ii) obtain regulatory approval to commence the marketing of our products, (iii) manage growth, (iv) achieve market acceptance or insurance reimbursement for any of our proposed products, if successfully developed, or (v) respond to competition. As a result, there can be no assurance that we will be able to develop or maintain consistent revenue sources, or that our operations will be profitable and/or generate positive cash flows.

Any forecasts we make about our operations may prove to be inaccurate. We must, among other things, determine appropriate risks, rewards, and level of investment in our product lines, respond to economic and market variables outside of our control, respond to competitive developments and continue to attract, retain, and motivate qualified employees. There can be no assurance that we will be successful in meeting these challenges and addressing such risks and the failure to do so could have a materially adverse effect on our business, results of operations, and financial condition. Our prospects must be considered in light of the risks, expenses, and difficulties frequently encountered by companies in the early stage of development. As a result of these risks, challenges, and uncertainties, the value of your investment could be significantly reduced or completely lost.

**If we are unable to successfully identify, develop, and commercialize any product candidates, or experience significant delays in doing so, our business, financial condition, and results of operations will be materially adversely affected.**

Our ability to generate revenue from sales of any of our product candidates, which we do not expect to occur for at least the next several years, if ever, will depend heavily on the timely and successful identification, development, regulatory approval, and eventual commercialization of any such product candidates, which may never occur. To date, we have not generated revenue from sales of any products, and we may never be able to develop, obtain regulatory approval for, or commercialize a marketable product. Before we generate any revenue from product sales of any of our current or potential future product candidates, we will need to manage preclinical, clinical, and manufacturing activities, including undertaking significant clinical development, obtain regulatory approval in multiple jurisdictions, establish manufacturing supply, including commercial manufacturing supply, and build a commercial organization, which will require substantial investment and significant marketing efforts. We may never receive regulatory approval for any of our product candidates, which would prevent us from marketing, promoting, or selling any of our product candidates and generating revenue.

**Our success depends on our ability to protect our intellectual property rights and proprietary technologies, and we may not be able to protect our intellectual property rights throughout the world.**

Patent rights are generally national or regional rights. The filing, prosecution, maintenance, and defense of patent rights on our platform technologies and product candidates worldwide would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may have a different scope and strength than do those in the United States. In addition, the laws of some foreign countries, particularly certain developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our intellectual property rights in all countries outside the United States or from making, using, selling, or importing products made using our intellectual property rights in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained intellectual property rights, including patent protection, to develop their own products and may also export otherwise infringing products to territories where we have intellectual property rights, including patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products and our patent or other intellectual property rights may not be effective or adequate to prevent them from competing.

**The Company's founders, directors and executive officers own or control a majority of the Company.**

Additionally, the holdings of the Company's directors and executive officers may increase in the future upon vesting or other maturation of exercise rights under any of the options or warrants they may hold or in the future be granted or if they otherwise acquire additional interest in the Company. The interests of such persons may differ from the interests of the Company's other stockholders, including purchasers of securities in the offering. As a result, in addition to their board seats and offices, such persons will have significant influence over and control all corporate actions requiring stockholder approval, irrespective of how the Company's other stockholders, including purchasers in the offering, may vote.

**The Company may not be able to accomplish its public listing, and a market may not develop for the Shares.**

The Company is planning to become publicly listed within 12 months from the date hereof. However, there is no assurance that such public listing will ever occur or that a market will ever develop for the sale of the Shares in either event.

<u>MISCELLANEOUS</u>

<u>Entire Agreement</u>. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Agreement.

<u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on date of transmission if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

<u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

<u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. Neither party may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party.

<u>No Third-Party Beneficiaries</u>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by any other Person.

<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Florida, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this shall be commenced exclusively in the state and federal courts sitting in Volusia County, Florida.

<u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

<u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a ".pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or ".pdf" signature page is an original thereof.

<u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

**<u>WAIVER OF JURY TRIAL</u>. <u>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</u>**

IN WITNESS WHEREOF, the parties hereto have caused this Subscription Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

---

| | |
|:---|:---|
| **JABEZ BIOSCIENCES, INC.** | **JABEZ BIOSCIENCES, INC.** |
| By: | /s/ Tamara Jovonovich |
|  | Tamara Jovonovich, President and CEO |

---

**PURCHASER(S) / AUTHORIZED SIGNER**

---

| | |
|:---|:---|
| Company Name: | MedTek, LLC |
| Signature: | /s/ Jim Bullard |
| Print Name: | Jim Bullard |
|  | First Last |
| Title: | Manager |
| SSN# or FEIN: |  |
| Street Address: | 2308 W 5<sup>th</sup> Street |
| City: | Plainview, TX 79072 |
| Phone: | 806-777-1158 |
| Email: | jbullard1@aol.com |

---

**REGISTRATION TYPE:** (Select only one)

☐ Individual ☒ Company ☐ Joint Tenants ☐ Custodian IRA Account F/B/O (fill in below)

☐ Trust / Trustee: ________________________________________________ Trust Date: ______________________

**IF CUSTODIAL IRA, PLEASE COMPLETE**

Authorized Signer: _______________________________________________________________________________

Registration Name: _______________________________________________________________________________

Tax ID #: ___________________________________________ Phone #: ____________________________________

Address: _______________________________________________________________________________________

## Ex1Sa-6

**Exhibit 6.15**

**JABEZ BIOSCIENCES, INC.**

**$3,000,000 PRIVATE OFFERING OF COMMON STOCK**

**<u>OFFERING MEMORANDUM AND SUBSCRIPTION AGREEMENT</u>**

This Subscription Agreement (this "<u>Agreement</u>") is dated as of <u>June 27, 2025</u> between Jabez Biosciences, Inc., a Florida corporation ("Jabez" or the "<u>Company</u>") and MedTek, LLC, a Florida limited liability company, ("<u>Purchaser</u>").

WHEREAS, the Company is in the process of selling up to $3,000,000 of Common Stock to certain accredited and/or sophisticated investors, with a minimum purchase amount of $500.

WHEREAS, the Common Stock is being sold to select accredited and non-accredited but sophisticated investors in a private offering under Regulation D, Rule 506(b) as of August 02, 2024; and

WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to Purchaser, and Purchaser desires to purchase from the Company, certain of those Common Stock of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

<u>THE OFFERING</u>

Terms of Offering. The Company is offering Class "A" Common Stock at $1 per share.

<u>Common Stock</u>. The Company is selling Class "A" Common Stock (the "Shares"), in advance of its planned public markets listing, at a price of $1 per share. The Company is planning to undertake a public listing on either a national exchange or the OTCQB or OTCQX within 12 months from the date of this offering. The Shares, once issued, will be restricted for a minimum of 6 months under applicable federal securities laws.

<u>PURCHASE AND SALE</u>

<u>Purchase Amount</u>. the Company agrees to sell, and Purchaser agrees to purchase:

a total of <u>150,000</u> Shares from Company at $1 per share

for a total purchase amount of $<u>150,000</u>.

Purchaser shall deliver to the Company, via wire transfer or a certified check, immediately available funds equal to such Purchaser's Purchase Amount as set forth herein.

<u>THE COMPANY</u>

Jabez Biosciences is a Clinical Stage Biotechnology company developing liquid and solid tumor therapies. The company's lead technology is a dihydroorotate dehydrogenase (DHODH) small molecule inhibitor. This proprietary small molecule is easily synthesized, encapsulated for oral dosing, and stores at room temperature. Strong pre-clinical data suggests that the Jabez molecule may be a safe and effective therapeutic in humans for a number of solid and liquid tumors, allowing for an Investigational New Drug application. Jabez's novel DHODH compound was created and developed by world class scientists at The Ohio State University James Cancer Hospital and Solove Research Institute . The drug inhibits tumor cell growth and survival by not allowing cells to repair and multiply. This treatment is considered a *targeted* therapy (unlike a chemotherapy) because it only effects proliferative diseases where the diseased cells need to grow at accelerated rates, such as cancer. The way normal cells repair and multiply is unaffected. The drug is Phase I ready with anticipated IND filing in June 2024 and anticipated study start in September/October 2024.

The DHODH inhibitor is anticipated to be a First Line Treatment, for several solid and liquid tumor types, many qualifying for FDA fast track, priority review, and orphan status, creating "first in the que" reviews from the FDA and shorter times to approval. The DHODH inhibitor class has become an increasingly popular inhibitor in recent years. The FDA approved multiple DHODH drug programs such as Sanofi's Arava®, indicated for rheumatoid arthritis, and Aubagio® indicated for multiple sclerosis.

The safety and efficacy of DHODH class is well known in the oncology space for blocking cell cycle progression and inducing apoptosis, which has led companies like Johnson & Johnson Innovative Medicine (J&J, formerly Janssen) to invest in their own DHODH program for Acute Myeloid Leukemia (AML). J&J's multi-year investment has no doubt stirred the interest of Big Pharma in this class of drug and should help validate Jabez' own program while increasing its intrinsic value. Interest in Jabez by other Big Pharma companies looking to expand their small molecule platforms may have some comfort level in the future because of J&J's program.

**<u>Officers and Directors</u>**

<u>Tamara Jovonovich – President, Chief Executive Officer and Director</u>. Tamara Jovonovich received a B.S. in Chemistry and a B.S.in Fine Arts from the University of Central Florida, 1996, and went on to earn her PhD. in Biophysical Chemistry at the University of Washington, 2000. Tamara completed her post-doctoral research at Stanford University and Lectured at San Jose University, before entering the pharmaceutical industry in Palo Alto, CA, 2004. Tamara has remained in the industry for 20 years, working at start-up and medium cap pharma companies across multiple disciplines for example Alexza Pharmaceuticals (acquired by Ferrer), Cypress Pharmaceuticals, and Pernix Therapeutics.

<u>Robert Lewis – Chief Operating Officer and Director</u>. Robert Lewis earned his B.S. in Chemistry & Biology from Columbia College. Robert went on to work at global companies like Teva and Sigma as well as mid-tier and small pharma. Robert was an equity partner of Cypress Pharmaceutical and held the position of CSO, heading the departments of Scientific Affairs, Clinical Affairs, Regulatory Affairs, and Domestic and International Business Development. Cypress sold to a publicly traded company (Pernix) in 2012 for $102M. Additionally, Robert is an equity partner and sits on the BOD in other start-up companies in Pharma and Medical Device fields.

<u>Brian Cogley – Chief Financial Officer</u>. Brian Cogley is a senior-level financial executive with over 15 years of experience in corporate finance and accounting across a variety of industries, including life sciences, pharmaceuticals, financial services, and manufacturing.

<u>Bruce A. Cassidy, Director.</u> Bruce Cassidy joined our Board of Directors in August of 2024. Since 2017 he has been the Chairman of the Board of Sarasota Green Group. He currently serves on other boards for various companies, including as chairman of the board of each of Arboreta Healthcare (August 2020), KeyStar Corporation (d/b/a Zensports) (August 2022), Loop Media, Inc. (Board Member February 2020 and Chairman January 2021) and as a member of the board of Oragenics, Inc. (October 2023). Mr. Cassidy was chosen to serve as a member of our Board of Directors due to his extensive leadership and business experience and as a CEO of a large company, as well as his service on other boards of directors.

<u>Martin Lewis, Director.</u> Mr. Lewis joined our Board of Directors in August of 2024. Mr. Lewis has over 40 years of experience in Accounting and is a Certified Public Accountant. Mr. Lewis joined his current firm, Lewis, Kaufman & Co., P.C., in 1983. Mr. Lewis has been very active in the professional accounting field, having active memberships for a number of years with the American Institute of C.P.A.s, Texas Society of C.P.A.s, National Society of Accountants for Cooperatives and the Management of Accounting Practice - West Texas Chapter.

<u>REPRESENTATIONS AND AGREEMENTS OF THE PARTIES</u>

<u>Company Representations.</u> The Company is a duly formed and valid entity existing under Florida law. The Company has all right and title to enter into this Agreement without condition or reservation. The Company has the full legal right and authority to issue the Shares purchased by Purchaser hereunder.

<u>Purchaser Representations.</u> Purchaser represents that he or she has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment and has so evaluated the merits and risks of such investment. Purchaser has been afforded full and complete opportunity to receive and review all business and financial information regarding the Company and its business and is satisfied as to the same. Purchaser is able to bear the economic risk of this investment and, at the present time, is able to afford a complete loss of such investment. Purchaser has had the opportunity to seek the advice of legal or financial advisers regarding this investment and has carefully reviewed all Risk Factors associated with this highly speculative and risky investment.

<u>RISK FACTORS</u>

The purchase of Shares is subject to a number of significant risks in the Company or businesses in which the Company operates. The following risk factors should be carefully considered.

**Investments in small businesses and start-up companies are often risky.**

Small businesses may depend heavily upon a single customer, supplier, or employee whose departure would seriously damage the Company's profitability. The demand for the Company's product may be seasonal or be impacted by the overall economy, or the Company could face other risks that are specific to its industry or type of business. The Company may also have difficulty competing against larger companies who can negotiate for better prices from suppliers, produce goods and services on a large scale more economically, or take advantage of bigger marketing budgets. Furthermore, a small business could face risks from lawsuits, governmental regulations, and other potential impediments to growth.

**The Company may need additional capital, which may not be available.**

The Company may require funds in excess of its existing cash resources to fund operating deficits, develop new products or services, establish, and expand its marketing capabilities, and finance general and administrative activities. Due to market conditions at the time the Company may need additional funding, or due to its financial condition at that time, it is possible that the Company will be unable to obtain additional funding as and when it needs it and that could significantly affect the success of the Company.

**The Company's management has broad discretion in how the Company use the net proceeds of an offering.**

The Company's management will have considerable discretion over the use of proceeds from their offering. You may not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.

**The Company faces significant competition and operates in a highly regulated industry.**

The Company operates in the areas of bio-technology products and services, which is a highly competitive industry. There is substantial competition in the industry and many of the competitors are larger companies with deeper resources than the Company. Therefore, the Company will face stiff competition as it seeks to grow and execute its business plan. In addition, the Company operates in a highly regulated industry and as a result can incur significant costs and regulatory hurdles in bringing its products to market. Competitors may be better financed and able to overcome these regulatory hurdles and as such the Company may be at a disadvantage in the marketplace as a result.

**The Company may not be able to manage its potential growth.**

For the Company to succeed, it needs to experience significant expansion. There can be no assurance that it will achieve this expansion. This expansion, if accomplished, may place a significant strain on the Company's management, operational and financial resources. To manage any material growth, the Company will be required to implement operational and financial systems, procedures and controls. It will also be required to expand its finance, administrative and operations staff. There can be no assurance that the Company's current and planned personnel, systems, procedures and controls will be adequate to support its future operations at any increased level. The Company's failure to manage growth effectively could have a material adverse effect on its business, results of operations and financial condition.

**The Company's success relies on market acceptance.**

While the Company believes that there will be significant customer demand for its products/services, there is no assurance that there will be broad market acceptance of the Company's product offerings. In such event, there may be a material adverse effect on the Company's results of operations and financial condition, and the Company may not be able to achieve its business goals.

**We have a limited operating history, which may make it difficult for investors to predict future performance based on current operations.**

We have a limited operating history upon which investors may base an evaluation of our potential future performance. In particular, our limited staff and operating history means that there is a high degree of uncertainty regarding our ability to (i) develop and commercialize our technologies and proposed products (ii) obtain regulatory approval to commence the marketing of our products, (iii) manage growth, (iv) achieve market acceptance or insurance reimbursement for any of our proposed products, if successfully developed, or (v) respond to competition. As a result, there can be no assurance that we will be able to develop or maintain consistent revenue sources, or that our operations will be profitable and/or generate positive cash flows.

Any forecasts we make about our operations may prove to be inaccurate. We must, among other things, determine appropriate risks, rewards, and level of investment in our product lines, respond to economic and market variables outside of our control, respond to competitive developments and continue to attract, retain, and motivate qualified employees. There can be no assurance that we will be successful in meeting these challenges and addressing such risks and the failure to do so could have a materially adverse effect on our business, results of operations, and financial condition. Our prospects must be considered in light of the risks, expenses, and difficulties frequently encountered by companies in the early stage of development. As a result of these risks, challenges, and uncertainties, the value of your investment could be significantly reduced or completely lost.

**If we are unable to successfully identify, develop, and commercialize any product candidates, or experience significant delays in doing so, our business, financial condition, and results of operations will be materially adversely affected.**

Our ability to generate revenue from sales of any of our product candidates, which we do not expect to occur for at least the next several years, if ever, will depend heavily on the timely and successful identification, development, regulatory approval, and eventual commercialization of any such product candidates, which may never occur. To date, we have not generated revenue from sales of any products, and we may never be able to develop, obtain regulatory approval for, or commercialize a marketable product. Before we generate any revenue from product sales of any of our current or potential future product candidates, we will need to manage preclinical, clinical, and manufacturing activities, including undertaking significant clinical development, obtain regulatory approval in multiple jurisdictions, establish manufacturing supply, including commercial manufacturing supply, and build a commercial organization, which will require substantial investment and significant marketing efforts. We may never receive regulatory approval for any of our product candidates, which would prevent us from marketing, promoting, or selling any of our product candidates and generating revenue.

**Our success depends on our ability to protect our intellectual property rights and proprietary technologies, and we may not be able to protect our intellectual property rights throughout the world.**

Patent rights are generally national or regional rights. The filing, prosecution, maintenance, and defense of patent rights on our platform technologies and product candidates worldwide would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may have a different scope and strength than do those in the United States. In addition, the laws of some foreign countries, particularly certain developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our intellectual property rights in all countries outside the United States or from making, using, selling, or importing products made using our intellectual property rights in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained intellectual property rights, including patent protection, to develop their own products and may also export otherwise infringing products to territories where we have intellectual property rights, including patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products and our patent or other intellectual property rights may not be effective or adequate to prevent them from competing.

**The Company's founders, directors and executive officers own or control a majority of the Company.**

Additionally, the holdings of the Company's directors and executive officers may increase in the future upon vesting or other maturation of exercise rights under any of the options or warrants they may hold or in the future be granted or if they otherwise acquire additional interest in the Company. The interests of such persons may differ from the interests of the Company's other stockholders, including purchasers of securities in the offering. As a result, in addition to their board seats and offices, such persons will have significant influence over and control all corporate actions requiring stockholder approval, irrespective of how the Company's other stockholders, including purchasers in the offering, may vote.

**The Company may not be able to accomplish its public listing, and a market may not develop for the Shares.**

The Company is planning to become publicly listed within 12 months from the date hereof. However, there is no assurance that such public listing will ever occur or that a market will ever develop for the sale of the Shares in either event.

<u>MISCELLANEOUS</u>

<u>Entire Agreement</u>. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Agreement.

<u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on date of transmission if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

<u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

<u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. Neither party may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party.

<u>No Third-Party Beneficiaries</u>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by any other Person.

<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Florida, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this shall be commenced exclusively in the state and federal courts sitting in Volusia County, Florida.

<u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

<u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a ".pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or ".pdf" signature page is an original thereof.

<u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

**<u>WAIVER OF JURY TRIAL</u>. <u>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</u>**

IN WITNESS WHEREOF, the parties hereto have caused this Subscription Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

---

| | |
|:---|:---|
| **JABEZ BIOSCIENCES, INC.** | **JABEZ BIOSCIENCES, INC.** |
| By: | /s/ Tamara Jovonovich |
|  | Tamara Jovonovich, President and CEO |

---

**PURCHASER(S) / AUTHORIZED SIGNER**

---

| | |
|:---|:---|
| Company Name: | MedTek, LLC |
| Signature: | /s/ Jim Bullard |
| Print Name: | Jim Bullard |
|  | First Last |
| Title: | <u>Manager</u> |
| SSN# or FEIN: |  |
| Street Address: | <u>2308 W 5<sup>th</sup> Street</u> |
| City: | Plainview, TX 79072 |
| Phone: | <u>806-777-1158</u> |
| Email: | <u>jbullard1@aol.com</u> |

---

**REGISTRATION TYPE:** (Select only one)

☐ Individual ☒ Company ☐ Joint Tenants ☐ Custodian IRA Account F/B/O (fill in below)

☐ Trust / Trustee: ________________________________________________ Trust Date: ______________________

**IF CUSTODIAL IRA, PLEASE COMPLETE**

Authorized Signer: _______________________________________________________________________________

Registration Name: _______________________________________________________________________________

Tax ID #: ___________________________________________ Phone #: ____________________________________

Address: _______________________________________________________________________________________

## Ex1Sa-6

**Exhibit 6.16**

**JABEZ BIOSCIENCES, INC.**

**$3,000,000 PRIVATE OFFERING OF COMMON STOCK**

**<u>OFFERING MEMORANDUM AND SUBSCRIPTION AGREEMENT</u>**

This Subscription Agreement (this "<u>Agreement</u>") is dated as of <u>July 28, 2025</u> between Jabez Biosciences, Inc., a Florida corporation ("Jabez" or the "<u>Company</u>") and MedTek, LLC, a Florida limited liability company, ("<u>Purchaser</u>").

WHEREAS, the Company is in the process of selling up to $3,000,000 of Common Stock to certain accredited and/or sophisticated investors, with a minimum purchase amount of $500.

WHEREAS, the Common Stock is being sold to select accredited and non-accredited but sophisticated investors in a private offering under Regulation D, Rule 506(b) as of August 02, 2024; and

WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to Purchaser, and Purchaser desires to purchase from the Company, certain of those Common Stock of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

<u>THE OFFERING</u>

Terms of Offering. The Company is offering Class "A" Common Stock at $1 per share.

<u>Common Stock</u>. The Company is selling Class "A" Common Stock (the "Shares"), in advance of its planned public markets listing, at a price of $1 per share. The Company is planning to undertake a public listing on either a national exchange or the OTCQB or OTCQX within 12 months from the date of this offering. The Shares, once issued, will be restricted for a minimum of 6 months under applicable federal securities laws.

<u>PURCHASE AND SALE</u>

<u>Purchase Amount</u>. the Company agrees to sell, and Purchaser agrees to purchase:

a total of <u>150,000</u> Shares from Company at $1 per share

for a total purchase amount of $<u>150,000</u>.

Purchaser shall deliver to the Company, via wire transfer or a certified check, immediately available funds equal to such Purchaser's Purchase Amount as set forth herein.

<u>THE COMPANY</u>

Jabez Biosciences is a Clinical Stage Biotechnology company developing liquid and solid tumor therapies. The company's lead technology is a dihydroorotate dehydrogenase (DHODH) small molecule inhibitor. This proprietary small molecule is easily synthesized, encapsulated for oral dosing, and stores at room temperature. Strong pre-clinical data suggests that the Jabez molecule may be a safe and effective therapeutic in humans for a number of solid and liquid tumors, allowing for an Investigational New Drug application. Jabez's novel DHODH compound was created and developed by world class scientists at The Ohio State University James Cancer Hospital and Solove Research Institute . The drug inhibits tumor cell growth and survival by not allowing cells to repair and multiply. This treatment is considered a *targeted* therapy (unlike a chemotherapy) because it only effects proliferative diseases where the diseased cells need to grow at accelerated rates, such as cancer. The way normal cells repair and multiply is unaffected. The drug is Phase I ready with anticipated IND filing in June 2024 and anticipated study start in September/October 2024.

The DHODH inhibitor is anticipated to be a First Line Treatment, for several solid and liquid tumor types, many qualifying for FDA fast track, priority review, and orphan status, creating "first in the que" reviews from the FDA and shorter times to approval. The DHODH inhibitor class has become an increasingly popular inhibitor in recent years. The FDA approved multiple DHODH drug programs such as Sanofi's Arava®, indicated for rheumatoid arthritis, and Aubagio® indicated for multiple sclerosis.

The safety and efficacy of DHODH class is well known in the oncology space for blocking cell cycle progression and inducing apoptosis, which has led companies like Johnson & Johnson Innovative Medicine (J&J, formerly Janssen) to invest in their own DHODH program for Acute Myeloid Leukemia (AML). J&J's multi-year investment has no doubt stirred the interest of Big Pharma in this class of drug and should help validate Jabez' own program while increasing its intrinsic value. Interest in Jabez by other Big Pharma companies looking to expand their small molecule platforms may have some comfort level in the future because of J&J's program.

**<u>Officers and Directors</u>**

<u>Tamara Jovonovich – President, Chief Executive Officer and Director</u>. Tamara Jovonovich received a B.S. in Chemistry and a B.S.in Fine Arts from the University of Central Florida, 1996, and went on to earn her PhD. in Biophysical Chemistry at the University of Washington, 2000. Tamara completed her post-doctoral research at Stanford University and Lectured at San Jose University, before entering the pharmaceutical industry in Palo Alto, CA, 2004. Tamara has remained in the industry for 20 years, working at start-up and medium cap pharma companies across multiple disciplines for example Alexza Pharmaceuticals (acquired by Ferrer), Cypress Pharmaceuticals, and Pernix Therapeutics.

<u>Robert Lewis – Chief Operating Officer and Director</u>. Robert Lewis earned his B.S. in Chemistry & Biology from Columbia College. Robert went on to work at global companies like Teva and Sigma as well as mid-tier and small pharma. Robert was an equity partner of Cypress Pharmaceutical and held the position of CSO, heading the departments of Scientific Affairs, Clinical Affairs, Regulatory Affairs, and Domestic and International Business Development. Cypress sold to a publicly traded company (Pernix) in 2012 for $102M. Additionally, Robert is an equity partner and sits on the BOD in other start-up companies in Pharma and Medical Device fields.

<u>Brian Cogley – Chief Financial Officer</u>. Brian Cogley is a senior-level financial executive with over 15 years of experience in corporate finance and accounting across a variety of industries, including life sciences, pharmaceuticals, financial services, and manufacturing.

<u>Bruce A. Cassidy, Director.</u> Bruce Cassidy joined our Board of Directors in August of 2024. Since 2017 he has been the Chairman of the Board of Sarasota Green Group. He currently serves on other boards for various companies, including as chairman of the board of each of Arboreta Healthcare (August 2020), KeyStar Corporation (d/b/a Zensports) (August 2022), Loop Media, Inc. (Board Member February 2020 and Chairman January 2021) and as a member of the board of Oragenics, Inc. (October 2023). Mr. Cassidy was chosen to serve as a member of our Board of Directors due to his extensive leadership and business experience and as a CEO of a large company, as well as his service on other boards of directors.

<u>Martin Lewis, Director.</u> Mr. Lewis joined our Board of Directors in August of 2024. Mr. Lewis has over 40 years of experience in Accounting and is a Certified Public Accountant. Mr. Lewis joined his current firm, Lewis, Kaufman & Co., P.C., in 1983. Mr. Lewis has been very active in the professional accounting field, having active memberships for a number of years with the American Institute of C.P.A.s, Texas Society of C.P.A.s, National Society of Accountants for Cooperatives and the Management of Accounting Practice - West Texas Chapter.

<u>REPRESENTATIONS AND AGREEMENTS OF THE PARTIES</u>

<u>Company Representations.</u> The Company is a duly formed and valid entity existing under Florida law. The Company has all right and title to enter into this Agreement without condition or reservation. The Company has the full legal right and authority to issue the Shares purchased by Purchaser hereunder.

<u>Purchaser Representations.</u> Purchaser represents that he or she has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment and has so evaluated the merits and risks of such investment. Purchaser has been afforded full and complete opportunity to receive and review all business and financial information regarding the Company and its business and is satisfied as to the same. Purchaser is able to bear the economic risk of this investment and, at the present time, is able to afford a complete loss of such investment. Purchaser has had the opportunity to seek the advice of legal or financial advisers regarding this investment and has carefully reviewed all Risk Factors associated with this highly speculative and risky investment.

<u>RISK FACTORS</u>

The purchase of Shares is subject to a number of significant risks in the Company or businesses in which the Company operates. The following risk factors should be carefully considered.

**Investments in small businesses and start-up companies are often risky.**

Small businesses may depend heavily upon a single customer, supplier, or employee whose departure would seriously damage the Company's profitability. The demand for the Company's product may be seasonal or be impacted by the overall economy, or the Company could face other risks that are specific to its industry or type of business. The Company may also have difficulty competing against larger companies who can negotiate for better prices from suppliers, produce goods and services on a large scale more economically, or take advantage of bigger marketing budgets. Furthermore, a small business could face risks from lawsuits, governmental regulations, and other potential impediments to growth.

**The Company may need additional capital, which may not be available.**

The Company may require funds in excess of its existing cash resources to fund operating deficits, develop new products or services, establish, and expand its marketing capabilities, and finance general and administrative activities. Due to market conditions at the time the Company may need additional funding, or due to its financial condition at that time, it is possible that the Company will be unable to obtain additional funding as and when it needs it and that could significantly affect the success of the Company.

**The Company's management has broad discretion in how the Company use the net proceeds of an offering.**

The Company's management will have considerable discretion over the use of proceeds from their offering. You may not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.

**The Company faces significant competition and operates in a highly regulated industry.**

The Company operates in the areas of bio-technology products and services, which is a highly competitive industry. There is substantial competition in the industry and many of the competitors are larger companies with deeper resources than the Company. Therefore, the Company will face stiff competition as it seeks to grow and execute its business plan. In addition, the Company operates in a highly regulated industry and as a result can incur significant costs and regulatory hurdles in bringing its products to market. Competitors may be better financed and able to overcome these regulatory hurdles and as such the Company may be at a disadvantage in the marketplace as a result.

**The Company may not be able to manage its potential growth.**

For the Company to succeed, it needs to experience significant expansion. There can be no assurance that it will achieve this expansion. This expansion, if accomplished, may place a significant strain on the Company's management, operational and financial resources. To manage any material growth, the Company will be required to implement operational and financial systems, procedures and controls. It will also be required to expand its finance, administrative and operations staff. There can be no assurance that the Company's current and planned personnel, systems, procedures and controls will be adequate to support its future operations at any increased level. The Company's failure to manage growth effectively could have a material adverse effect on its business, results of operations and financial condition.

**The Company's success relies on market acceptance.**

While the Company believes that there will be significant customer demand for its products/services, there is no assurance that there will be broad market acceptance of the Company's product offerings. In such event, there may be a material adverse effect on the Company's results of operations and financial condition, and the Company may not be able to achieve its business goals.

**We have a limited operating history, which may make it difficult for investors to predict future performance based on current operations.**

We have a limited operating history upon which investors may base an evaluation of our potential future performance. In particular, our limited staff and operating history means that there is a high degree of uncertainty regarding our ability to (i) develop and commercialize our technologies and proposed products (ii) obtain regulatory approval to commence the marketing of our products, (iii) manage growth, (iv) achieve market acceptance or insurance reimbursement for any of our proposed products, if successfully developed, or (v) respond to competition. As a result, there can be no assurance that we will be able to develop or maintain consistent revenue sources, or that our operations will be profitable and/or generate positive cash flows.

Any forecasts we make about our operations may prove to be inaccurate. We must, among other things, determine appropriate risks, rewards, and level of investment in our product lines, respond to economic and market variables outside of our control, respond to competitive developments and continue to attract, retain, and motivate qualified employees. There can be no assurance that we will be successful in meeting these challenges and addressing such risks and the failure to do so could have a materially adverse effect on our business, results of operations, and financial condition. Our prospects must be considered in light of the risks, expenses, and difficulties frequently encountered by companies in the early stage of development. As a result of these risks, challenges, and uncertainties, the value of your investment could be significantly reduced or completely lost.

**If we are unable to successfully identify, develop, and commercialize any product candidates, or experience significant delays in doing so, our business, financial condition, and results of operations will be materially adversely affected.**

Our ability to generate revenue from sales of any of our product candidates, which we do not expect to occur for at least the next several years, if ever, will depend heavily on the timely and successful identification, development, regulatory approval, and eventual commercialization of any such product candidates, which may never occur. To date, we have not generated revenue from sales of any products, and we may never be able to develop, obtain regulatory approval for, or commercialize a marketable product. Before we generate any revenue from product sales of any of our current or potential future product candidates, we will need to manage preclinical, clinical, and manufacturing activities, including undertaking significant clinical development, obtain regulatory approval in multiple jurisdictions, establish manufacturing supply, including commercial manufacturing supply, and build a commercial organization, which will require substantial investment and significant marketing efforts. We may never receive regulatory approval for any of our product candidates, which would prevent us from marketing, promoting, or selling any of our product candidates and generating revenue.

**Our success depends on our ability to protect our intellectual property rights and proprietary technologies, and we may not be able to protect our intellectual property rights throughout the world.**

Patent rights are generally national or regional rights. The filing, prosecution, maintenance, and defense of patent rights on our platform technologies and product candidates worldwide would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may have a different scope and strength than do those in the United States. In addition, the laws of some foreign countries, particularly certain developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our intellectual property rights in all countries outside the United States or from making, using, selling, or importing products made using our intellectual property rights in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained intellectual property rights, including patent protection, to develop their own products and may also export otherwise infringing products to territories where we have intellectual property rights, including patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products and our patent or other intellectual property rights may not be effective or adequate to prevent them from competing.

**The Company's founders, directors and executive officers own or control a majority of the Company.**

Additionally, the holdings of the Company's directors and executive officers may increase in the future upon vesting or other maturation of exercise rights under any of the options or warrants they may hold or in the future be granted or if they otherwise acquire additional interest in the Company. The interests of such persons may differ from the interests of the Company's other stockholders, including purchasers of securities in the offering. As a result, in addition to their board seats and offices, such persons will have significant influence over and control all corporate actions requiring stockholder approval, irrespective of how the Company's other stockholders, including purchasers in the offering, may vote.

**The Company may not be able to accomplish its public listing, and a market may not develop for the Shares.**

The Company is planning to become publicly listed within 12 months from the date hereof. However, there is no assurance that such public listing will ever occur or that a market will ever develop for the sale of the Shares in either event.

<u>MISCELLANEOUS</u>

<u>Entire Agreement</u>. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Agreement.

<u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on date of transmission if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

<u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

<u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. Neither party may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party.

<u>No Third-Party Beneficiaries</u>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by any other Person.

<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Florida, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this shall be commenced exclusively in the state and federal courts sitting in Volusia County, Florida.

<u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

<u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a ".pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or ".pdf" signature page is an original thereof.

<u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

**<u>WAIVER OF JURY TRIAL</u>. <u>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</u>**

IN WITNESS WHEREOF, the parties hereto have caused this Subscription Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

---

| | |
|:---|:---|
| **JABEZ BIOSCIENCES, INC.** | **JABEZ BIOSCIENCES, INC.** |
| By: | /s/ Tamara Jovonovich |
|  | Tamara Jovonovich, President and CEO |

---

**PURCHASER(S) / AUTHORIZED SIGNER**

---

| | |
|:---|:---|
| Company Name: | <u>MedTek, LLC</u> |
| Signature: | /s/ Jim Bullard |
| Print Name: | Jim Bullard |
|  | First Last |
| Title: | <u>Manager</u> |
| SSN# or FEIN: |  |
| Street Address: | <u>2308 W 5<sup>th</sup> Street</u> |
| City: | <u>Plainview</u>, TX 79072 |
| Phone: | <u>806-777-1158</u> |
| Email: | <u>jbullard1@aol.com</u> |

---

**REGISTRATION TYPE:** (Select only one)

☐ Individual ☒ Company ☐ Joint Tenants ☐ Custodian IRA Account F/B/O (fill in below)

☐ Trust / Trustee: ________________________________________________ Trust Date: ______________________

**IF CUSTODIAL IRA, PLEASE COMPLETE**

Authorized Signer: _______________________________________________________________________________

Registration Name: _______________________________________________________________________________

Tax ID #: ___________________________________________ Phone #: ____________________________________

Address: _______________________________________________________________________________________

## Ex1Sa-6

**Exhibit 6.17**

**JABEZ BIOSCIENCES, INC.**

**$3,000,000 PRIVATE OFFERING OF COMMON STOCK**

**<u>OFFERING MEMORANDUM AND SUBSCRIPTION AGREEMENT</u>**

This Subscription Agreement (this "<u>Agreement</u>") is dated as of <u>August 29, 2025</u> between Jabez Biosciences, Inc., a Florida corporation ("Jabez" or the "<u>Company</u>") and MedTek, LLC, a Florida limited liability company, ("<u>Purchaser</u>").

WHEREAS, the Company is in the process of selling up to $3,000,000 of Common Stock to certain accredited and/or sophisticated investors, with a minimum purchase amount of $500.

WHEREAS, the Common Stock is being sold to select accredited and non-accredited but sophisticated investors in a private offering under Regulation D, Rule 506(b) as of August 02, 2024; and

WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to Purchaser, and Purchaser desires to purchase from the Company, certain of those Common Stock of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

<u>THE OFFERING</u>

Terms of Offering. The Company is offering Class "A" Common Stock at $1 per share.

<u>Common Stock</u>. The Company is selling Class "A" Common Stock (the "Shares"), in advance of its planned public markets listing, at a price of $1 per share. The Company is planning to undertake a public listing on either a national exchange or the OTCQB or OTCQX within 12 months from the date of this offering. The Shares, once issued, will be restricted for a minimum of 6 months under applicable federal securities laws.

<u>PURCHASE AND SALE</u>

<u>Purchase Amount</u>. the Company agrees to sell, and Purchaser agrees to purchase:

a total of <u>150,000</u> Shares from Company at $1 per share

for a total purchase amount of $<u>150,000</u>.

Purchaser shall deliver to the Company, via wire transfer or a certified check, immediately available funds equal to such Purchaser's Purchase Amount as set forth herein.

<u>THE COMPANY</u>

Jabez Biosciences is a Clinical Stage Biotechnology company developing liquid and solid tumor therapies. The company's lead technology is a dihydroorotate dehydrogenase (DHODH) small molecule inhibitor. This proprietary small molecule is easily synthesized, encapsulated for oral dosing, and stores at room temperature. Strong pre-clinical data suggests that the Jabez molecule may be a safe and effective therapeutic in humans for a number of solid and liquid tumors, allowing for an Investigational New Drug application. Jabez's novel DHODH compound was created and developed by world class scientists at The Ohio State University James Cancer Hospital and Solove Research Institute . The drug inhibits tumor cell growth and survival by not allowing cells to repair and multiply. This treatment is considered a *targeted* therapy (unlike a chemotherapy) because it only effects proliferative diseases where the diseased cells need to grow at accelerated rates, such as cancer. The way normal cells repair and multiply is unaffected. The drug is Phase I ready with anticipated IND filing in June 2024 and anticipated study start in September/October 2024.

The DHODH inhibitor is anticipated to be a First Line Treatment, for several solid and liquid tumor types, many qualifying for FDA fast track, priority review, and orphan status, creating "first in the que" reviews from the FDA and shorter times to approval. The DHODH inhibitor class has become an increasingly popular inhibitor in recent years. The FDA approved multiple DHODH drug programs such as Sanofi's Arava®, indicated for rheumatoid arthritis, and Aubagio® indicated for multiple sclerosis.

The safety and efficacy of DHODH class is well known in the oncology space for blocking cell cycle progression and inducing apoptosis, which has led companies like Johnson & Johnson Innovative Medicine (J&J, formerly Janssen) to invest in their own DHODH program for Acute Myeloid Leukemia (AML). J&J's multi-year investment has no doubt stirred the interest of Big Pharma in this class of drug and should help validate Jabez' own program while increasing its intrinsic value. Interest in Jabez by other Big Pharma companies looking to expand their small molecule platforms may have some comfort level in the future because of J&J's program.

**<u>Officers and Directors</u>**

<u>Tamara Jovonovich – President, Chief Executive Officer and Director</u>. Tamara Jovonovich received a B.S. in Chemistry and a B.S.in Fine Arts from the University of Central Florida, 1996, and went on to earn her PhD. in Biophysical Chemistry at the University of Washington, 2000. Tamara completed her post-doctoral research at Stanford University and Lectured at San Jose University, before entering the pharmaceutical industry in Palo Alto, CA, 2004. Tamara has remained in the industry for 20 years, working at start-up and medium cap pharma companies across multiple disciplines for example Alexza Pharmaceuticals (acquired by Ferrer), Cypress Pharmaceuticals, and Pernix Therapeutics.

<u>Robert Lewis – Chief Operating Officer and Director</u>. Robert Lewis earned his B.S. in Chemistry & Biology from Columbia College. Robert went on to work at global companies like Teva and Sigma as well as mid-tier and small pharma. Robert was an equity partner of Cypress Pharmaceutical and held the position of CSO, heading the departments of Scientific Affairs, Clinical Affairs, Regulatory Affairs, and Domestic and International Business Development. Cypress sold to a publicly traded company (Pernix) in 2012 for $102M. Additionally, Robert is an equity partner and sits on the BOD in other start-up companies in Pharma and Medical Device fields.

<u>Brian Cogley – Chief Financial Officer</u>. Brian Cogley is a senior-level financial executive with over 15 years of experience in corporate finance and accounting across a variety of industries, including life sciences, pharmaceuticals, financial services, and manufacturing.

<u>Bruce A. Cassidy, Director.</u> Bruce Cassidy joined our Board of Directors in August of 2024. Since 2017 he has been the Chairman of the Board of Sarasota Green Group. He currently serves on other boards for various companies, including as chairman of the board of each of Arboreta Healthcare (August 2020), KeyStar Corporation (d/b/a Zensports) (August 2022), Loop Media, Inc. (Board Member February 2020 and Chairman January 2021) and as a member of the board of Oragenics, Inc. (October 2023). Mr. Cassidy was chosen to serve as a member of our Board of Directors due to his extensive leadership and business experience and as a CEO of a large company, as well as his service on other boards of directors.

<u>Martin Lewis, Director.</u> Mr. Lewis joined our Board of Directors in August of 2024. Mr. Lewis has over 40 years of experience in Accounting and is a Certified Public Accountant. Mr. Lewis joined his current firm, Lewis, Kaufman & Co., P.C., in 1983. Mr. Lewis has been very active in the professional accounting field, having active memberships for a number of years with the American Institute of C.P.A.s, Texas Society of C.P.A.s, National Society of Accountants for Cooperatives and the Management of Accounting Practice - West Texas Chapter.

<u>REPRESENTATIONS AND AGREEMENTS OF THE PARTIES</u>

<u>Company Representations.</u> The Company is a duly formed and valid entity existing under Florida law. The Company has all right and title to enter into this Agreement without condition or reservation. The Company has the full legal right and authority to issue the Shares purchased by Purchaser hereunder.

<u>Purchaser Representations.</u> Purchaser represents that he or she has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment and has so evaluated the merits and risks of such investment. Purchaser has been afforded full and complete opportunity to receive and review all business and financial information regarding the Company and its business and is satisfied as to the same. Purchaser is able to bear the economic risk of this investment and, at the present time, is able to afford a complete loss of such investment. Purchaser has had the opportunity to seek the advice of legal or financial advisers regarding this investment and has carefully reviewed all Risk Factors associated with this highly speculative and risky investment.

<u>RISK FACTORS</u>

The purchase of Shares is subject to a number of significant risks in the Company or businesses in which the Company operates. The following risk factors should be carefully considered.

**Investments in small businesses and start-up companies are often risky.**

Small businesses may depend heavily upon a single customer, supplier, or employee whose departure would seriously damage the Company's profitability. The demand for the Company's product may be seasonal or be impacted by the overall economy, or the Company could face other risks that are specific to its industry or type of business. The Company may also have difficulty competing against larger companies who can negotiate for better prices from suppliers, produce goods and services on a large scale more economically, or take advantage of bigger marketing budgets. Furthermore, a small business could face risks from lawsuits, governmental regulations, and other potential impediments to growth.

**The Company may need additional capital, which may not be available.**

The Company may require funds in excess of its existing cash resources to fund operating deficits, develop new products or services, establish, and expand its marketing capabilities, and finance general and administrative activities. Due to market conditions at the time the Company may need additional funding, or due to its financial condition at that time, it is possible that the Company will be unable to obtain additional funding as and when it needs it and that could significantly affect the success of the Company.

**The Company's management has broad discretion in how the Company use the net proceeds of an offering.**

The Company's management will have considerable discretion over the use of proceeds from their offering. You may not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.

**The Company faces significant competition and operates in a highly regulated industry.**

The Company operates in the areas of bio-technology products and services, which is a highly competitive industry. There is substantial competition in the industry and many of the competitors are larger companies with deeper resources than the Company. Therefore, the Company will face stiff competition as it seeks to grow and execute its business plan. In addition, the Company operates in a highly regulated industry and as a result can incur significant costs and regulatory hurdles in bringing its products to market. Competitors may be better financed and able to overcome these regulatory hurdles and as such the Company may be at a disadvantage in the marketplace as a result.

**The Company may not be able to manage its potential growth.**

For the Company to succeed, it needs to experience significant expansion. There can be no assurance that it will achieve this expansion. This expansion, if accomplished, may place a significant strain on the Company's management, operational and financial resources. To manage any material growth, the Company will be required to implement operational and financial systems, procedures and controls. It will also be required to expand its finance, administrative and operations staff. There can be no assurance that the Company's current and planned personnel, systems, procedures and controls will be adequate to support its future operations at any increased level. The Company's failure to manage growth effectively could have a material adverse effect on its business, results of operations and financial condition.

**The Company's success relies on market acceptance.**

While the Company believes that there will be significant customer demand for its products/services, there is no assurance that there will be broad market acceptance of the Company's product offerings. In such event, there may be a material adverse effect on the Company's results of operations and financial condition, and the Company may not be able to achieve its business goals.

**We have a limited operating history, which may make it difficult for investors to predict future performance based on current operations.**

We have a limited operating history upon which investors may base an evaluation of our potential future performance. In particular, our limited staff and operating history means that there is a high degree of uncertainty regarding our ability to (i) develop and commercialize our technologies and proposed products (ii) obtain regulatory approval to commence the marketing of our products, (iii) manage growth, (iv) achieve market acceptance or insurance reimbursement for any of our proposed products, if successfully developed, or (v) respond to competition. As a result, there can be no assurance that we will be able to develop or maintain consistent revenue sources, or that our operations will be profitable and/or generate positive cash flows.

Any forecasts we make about our operations may prove to be inaccurate. We must, among other things, determine appropriate risks, rewards, and level of investment in our product lines, respond to economic and market variables outside of our control, respond to competitive developments and continue to attract, retain, and motivate qualified employees. There can be no assurance that we will be successful in meeting these challenges and addressing such risks and the failure to do so could have a materially adverse effect on our business, results of operations, and financial condition. Our prospects must be considered in light of the risks, expenses, and difficulties frequently encountered by companies in the early stage of development. As a result of these risks, challenges, and uncertainties, the value of your investment could be significantly reduced or completely lost.

**If we are unable to successfully identify, develop, and commercialize any product candidates, or experience significant delays in doing so, our business, financial condition, and results of operations will be materially adversely affected.**

Our ability to generate revenue from sales of any of our product candidates, which we do not expect to occur for at least the next several years, if ever, will depend heavily on the timely and successful identification, development, regulatory approval, and eventual commercialization of any such product candidates, which may never occur. To date, we have not generated revenue from sales of any products, and we may never be able to develop, obtain regulatory approval for, or commercialize a marketable product. Before we generate any revenue from product sales of any of our current or potential future product candidates, we will need to manage preclinical, clinical, and manufacturing activities, including undertaking significant clinical development, obtain regulatory approval in multiple jurisdictions, establish manufacturing supply, including commercial manufacturing supply, and build a commercial organization, which will require substantial investment and significant marketing efforts. We may never receive regulatory approval for any of our product candidates, which would prevent us from marketing, promoting, or selling any of our product candidates and generating revenue.

**Our success depends on our ability to protect our intellectual property rights and proprietary technologies, and we may not be able to protect our intellectual property rights throughout the world.**

Patent rights are generally national or regional rights. The filing, prosecution, maintenance, and defense of patent rights on our platform technologies and product candidates worldwide would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may have a different scope and strength than do those in the United States. In addition, the laws of some foreign countries, particularly certain developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our intellectual property rights in all countries outside the United States or from making, using, selling, or importing products made using our intellectual property rights in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained intellectual property rights, including patent protection, to develop their own products and may also export otherwise infringing products to territories where we have intellectual property rights, including patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products and our patent or other intellectual property rights may not be effective or adequate to prevent them from competing.

**The Company's founders, directors and executive officers own or control a majority of the Company.**

Additionally, the holdings of the Company's directors and executive officers may increase in the future upon vesting or other maturation of exercise rights under any of the options or warrants they may hold or in the future be granted or if they otherwise acquire additional interest in the Company. The interests of such persons may differ from the interests of the Company's other stockholders, including purchasers of securities in the offering. As a result, in addition to their board seats and offices, such persons will have significant influence over and control all corporate actions requiring stockholder approval, irrespective of how the Company's other stockholders, including purchasers in the offering, may vote.

**The Company may not be able to accomplish its public listing, and a market may not develop for the Shares.**

The Company is planning to become publicly listed within 12 months from the date hereof. However, there is no assurance that such public listing will ever occur or that a market will ever develop for the sale of the Shares in either event.

<u>MISCELLANEOUS</u>

<u>Entire Agreement</u>. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Agreement.

<u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on date of transmission if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

<u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

<u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. Neither party may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party.

<u>No Third-Party Beneficiaries</u>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by any other Person.

<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Florida, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this shall be commenced exclusively in the state and federal courts sitting in Volusia County, Florida.

<u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

<u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a ".pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or ".pdf" signature page is an original thereof.

<u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

**<u>WAIVER OF JURY TRIAL</u>. <u>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</u>**

IN WITNESS WHEREOF, the parties hereto have caused this Subscription Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

---

| | |
|:---|:---|
| **JABEZ BIOSCIENCES, INC.** | **JABEZ BIOSCIENCES, INC.** |
| By: | /s/ Tamara Jovonovich |
|  | Tamara Jovonovich, President and CEO |

---

**PURCHASER(S) / AUTHORIZED SIGNER**

---

| | |
|:---|:---|
| Company Name: | <u>MedTek, LLC</u> |
| Signature: | /s/ Jim Bullard |
| Print Name: | Jim Bullard |
|  | First Last |
| Title: | <u>Manager</u> |
| SSN# or FEIN: |  |
| Street Address: | <u>2308 W 5<sup>th</sup> Street</u> |
| City: | <u>Plainview</u>,<u>TX</u> 79072 |
| Phone: | <u>806-777-1158</u> |
| Email: | <u>jbullard1@aol.com</u> |

---

**REGISTRATION TYPE:** (Select only one)

☐ Individual ☒ Company ☐ Joint Tenants ☐ Custodian IRA Account F/B/O (fill in below)

☐ Trust / Trustee: ________________________________________________ Trust Date: ______________________

**IF CUSTODIAL IRA, PLEASE COMPLETE**

Authorized Signer: ________________________________________________________________________________

Registration Name: ________________________________________________________________________________

Tax ID #: ___________________________________________ Phone #: ____________________________________

Address:<u> </u>

## Ex1Sa-6

**Exhibit 6.18**

**JABEZ BIOSCIENCES, INC.**

**$3,000,000 PRIVATE OFFERING OF COMMON STOCK**

**<u>OFFERING MEMORANDUM AND SUBSCRIPTION AGREEMENT</u>**

This Subscription Agreement (this "<u>Agreement</u>") is dated as of <u>September 26, 2025</u> between Jabez Biosciences, Inc., a Florida corporation ("Jabez" or the "<u>Company</u>") and MedTek, LLC, a Florida limited liability company, ("<u>Purchaser</u>").

WHEREAS, the Company is in the process of selling up to $3,000,000 of Common Stock to certain accredited and/or sophisticated investors, with a minimum purchase amount of $500.

WHEREAS, the Common Stock is being sold to select accredited and non-accredited but sophisticated investors in a private offering under Regulation D, Rule 506(b) as of August 02, 2024; and

WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to Purchaser, and Purchaser desires to purchase from the Company, certain of those Common Stock of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

<u>THE OFFERING</u>

Terms of Offering. The Company is offering Class "A" Common Stock at $1 per share.

<u>Common Stock</u>. The Company is selling Class "A" Common Stock (the "Shares"), in advance of its planned public markets listing, at a price of $1 per share. The Company is planning to undertake a public listing on either a national exchange or the OTCQB or OTCQX within 12 months from the date of this offering. The Shares, once issued, will be restricted for a minimum of 6 months under applicable federal securities laws.

<u>PURCHASE AND SALE</u>

<u>Purchase Amount</u>. the Company agrees to sell, and Purchaser agrees to purchase:

a total of <u>150,000</u> Shares from Company at $1 per share

for a total purchase amount of $<u>150,000</u>.

Purchaser shall deliver to the Company, via wire transfer or a certified check, immediately available funds equal to such Purchaser's Purchase Amount as set forth herein.

<u>THE COMPANY</u>

Jabez Biosciences is a Clinical Stage Biotechnology company developing liquid and solid tumor therapies. The company's lead technology is a dihydroorotate dehydrogenase (DHODH) small molecule inhibitor. This proprietary small molecule is easily synthesized, encapsulated for oral dosing, and stores at room temperature. Strong pre-clinical data suggests that the Jabez molecule may be a safe and effective therapeutic in humans for a number of solid and liquid tumors, allowing for an Investigational New Drug application. Jabez's novel DHODH compound was created and developed by world class scientists at The Ohio State University James Cancer Hospital and Solove Research Institute . The drug inhibits tumor cell growth and survival by not allowing cells to repair and multiply. This treatment is considered a *targeted* therapy (unlike a chemotherapy) because it only effects proliferative diseases where the diseased cells need to grow at accelerated rates, such as cancer. The way normal cells repair and multiply is unaffected. The drug is Phase I ready with anticipated IND filing in June 2024 and anticipated study start in September/October 2024.

The DHODH inhibitor is anticipated to be a First Line Treatment, for several solid and liquid tumor types, many qualifying for FDA fast track, priority review, and orphan status, creating "first in the que" reviews from the FDA and shorter times to approval. The DHODH inhibitor class has become an increasingly popular inhibitor in recent years. The FDA approved multiple DHODH drug programs such as Sanofi's Arava®, indicated for rheumatoid arthritis, and Aubagio® indicated for multiple sclerosis.

The safety and efficacy of DHODH class is well known in the oncology space for blocking cell cycle progression and inducing apoptosis, which has led companies like Johnson & Johnson Innovative Medicine (J&J, formerly Janssen) to invest in their own DHODH program for Acute Myeloid Leukemia (AML). J&J's multi-year investment has no doubt stirred the interest of Big Pharma in this class of drug and should help validate Jabez' own program while increasing its intrinsic value. Interest in Jabez by other Big Pharma companies looking to expand their small molecule platforms may have some comfort level in the future because of J&J's program.

**<u>Officers and Directors</u>**

<u>Tamara Jovonovich – President, Chief Executive Officer and Director</u>. Tamara Jovonovich received a B.S. in Chemistry and a B.S.in Fine Arts from the University of Central Florida, 1996, and went on to earn her PhD. in Biophysical Chemistry at the University of Washington, 2000. Tamara completed her post-doctoral research at Stanford University and Lectured at San Jose University, before entering the pharmaceutical industry in Palo Alto, CA, 2004. Tamara has remained in the industry for 20 years, working at start-up and medium cap pharma companies across multiple disciplines for example Alexza Pharmaceuticals (acquired by Ferrer), Cypress Pharmaceuticals, and Pernix Therapeutics.

<u>Robert Lewis – Chief Operating Officer and Director</u>. Robert Lewis earned his B.S. in Chemistry & Biology from Columbia College. Robert went on to work at global companies like Teva and Sigma as well as mid-tier and small pharma. Robert was an equity partner of Cypress Pharmaceutical and held the position of CSO, heading the departments of Scientific Affairs, Clinical Affairs, Regulatory Affairs, and Domestic and International Business Development. Cypress sold to a publicly traded company (Pernix) in 2012 for $102M. Additionally, Robert is an equity partner and sits on the BOD in other start-up companies in Pharma and Medical Device fields.

<u>Brian Cogley – Chief Financial Officer</u>. Brian Cogley is a senior-level financial executive with over 15 years of experience in corporate finance and accounting across a variety of industries, including life sciences, pharmaceuticals, financial services, and manufacturing.

<u>Bruce A. Cassidy, Director.</u> Bruce Cassidy joined our Board of Directors in August of 2024. Since 2017 he has been the Chairman of the Board of Sarasota Green Group. He currently serves on other boards for various companies, including as chairman of the board of each of Arboreta Healthcare (August 2020), KeyStar Corporation (d/b/a Zensports) (August 2022), Loop Media, Inc. (Board Member February 2020 and Chairman January 2021) and as a member of the board of Oragenics, Inc. (October 2023). Mr. Cassidy was chosen to serve as a member of our Board of Directors due to his extensive leadership and business experience and as a CEO of a large company, as well as his service on other boards of directors.

<u>Martin Lewis, Director.</u> Mr. Lewis joined our Board of Directors in August of 2024. Mr. Lewis has over 40 years of experience in Accounting and is a Certified Public Accountant. Mr. Lewis joined his current firm, Lewis, Kaufman & Co., P.C., in 1983. Mr. Lewis has been very active in the professional accounting field, having active memberships for a number of years with the American Institute of C.P.A.s, Texas Society of C.P.A.s, National Society of Accountants for Cooperatives and the Management of Accounting Practice - West Texas Chapter.

<u>REPRESENTATIONS AND AGREEMENTS OF THE PARTIES</u>

<u>Company Representations.</u> The Company is a duly formed and valid entity existing under Florida law. The Company has all right and title to enter into this Agreement without condition or reservation. The Company has the full legal right and authority to issue the Shares purchased by Purchaser hereunder.

<u>Purchaser Representations.</u> Purchaser represents that he or she has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment and has so evaluated the merits and risks of such investment. Purchaser has been afforded full and complete opportunity to receive and review all business and financial information regarding the Company and its business and is satisfied as to the same. Purchaser is able to bear the economic risk of this investment and, at the present time, is able to afford a complete loss of such investment. Purchaser has had the opportunity to seek the advice of legal or financial advisers regarding this investment and has carefully reviewed all Risk Factors associated with this highly speculative and risky investment.

<u>RISK FACTORS</u>

The purchase of Shares is subject to a number of significant risks in the Company or businesses in which the Company operates. The following risk factors should be carefully considered.

**Investments in small businesses and start-up companies are often risky.**

Small businesses may depend heavily upon a single customer, supplier, or employee whose departure would seriously damage the Company's profitability. The demand for the Company's product may be seasonal or be impacted by the overall economy, or the Company could face other risks that are specific to its industry or type of business. The Company may also have difficulty competing against larger companies who can negotiate for better prices from suppliers, produce goods and services on a large scale more economically, or take advantage of bigger marketing budgets. Furthermore, a small business could face risks from lawsuits, governmental regulations, and other potential impediments to growth.

**The Company may need additional capital, which may not be available.**

The Company may require funds in excess of its existing cash resources to fund operating deficits, develop new products or services, establish, and expand its marketing capabilities, and finance general and administrative activities. Due to market conditions at the time the Company may need additional funding, or due to its financial condition at that time, it is possible that the Company will be unable to obtain additional funding as and when it needs it and that could significantly affect the success of the Company.

**The Company's management has broad discretion in how the Company use the net proceeds of an offering.**

The Company's management will have considerable discretion over the use of proceeds from their offering. You may not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.

**The Company faces significant competition and operates in a highly regulated industry.**

The Company operates in the areas of bio-technology products and services, which is a highly competitive industry. There is substantial competition in the industry and many of the competitors are larger companies with deeper resources than the Company. Therefore, the Company will face stiff competition as it seeks to grow and execute its business plan. In addition, the Company operates in a highly regulated industry and as a result can incur significant costs and regulatory hurdles in bringing its products to market. Competitors may be better financed and able to overcome these regulatory hurdles and as such the Company may be at a disadvantage in the marketplace as a result.

**The Company may not be able to manage its potential growth.**

For the Company to succeed, it needs to experience significant expansion. There can be no assurance that it will achieve this expansion. This expansion, if accomplished, may place a significant strain on the Company's management, operational and financial resources. To manage any material growth, the Company will be required to implement operational and financial systems, procedures and controls. It will also be required to expand its finance, administrative and operations staff. There can be no assurance that the Company's current and planned personnel, systems, procedures and controls will be adequate to support its future operations at any increased level. The Company's failure to manage growth effectively could have a material adverse effect on its business, results of operations and financial condition.

**The Company's success relies on market acceptance.**

While the Company believes that there will be significant customer demand for its products/services, there is no assurance that there will be broad market acceptance of the Company's product offerings. In such event, there may be a material adverse effect on the Company's results of operations and financial condition, and the Company may not be able to achieve its business goals.

**We have a limited operating history, which may make it difficult for investors to predict future performance based on current operations.**

We have a limited operating history upon which investors may base an evaluation of our potential future performance. In particular, our limited staff and operating history means that there is a high degree of uncertainty regarding our ability to (i) develop and commercialize our technologies and proposed products (ii) obtain regulatory approval to commence the marketing of our products, (iii) manage growth, (iv) achieve market acceptance or insurance reimbursement for any of our proposed products, if successfully developed, or (v) respond to competition. As a result, there can be no assurance that we will be able to develop or maintain consistent revenue sources, or that our operations will be profitable and/or generate positive cash flows.

Any forecasts we make about our operations may prove to be inaccurate. We must, among other things, determine appropriate risks, rewards, and level of investment in our product lines, respond to economic and market variables outside of our control, respond to competitive developments and continue to attract, retain, and motivate qualified employees. There can be no assurance that we will be successful in meeting these challenges and addressing such risks and the failure to do so could have a materially adverse effect on our business, results of operations, and financial condition. Our prospects must be considered in light of the risks, expenses, and difficulties frequently encountered by companies in the early stage of development. As a result of these risks, challenges, and uncertainties, the value of your investment could be significantly reduced or completely lost.

**If we are unable to successfully identify, develop, and commercialize any product candidates, or experience significant delays in doing so, our business, financial condition, and results of operations will be materially adversely affected.**

Our ability to generate revenue from sales of any of our product candidates, which we do not expect to occur for at least the next several years, if ever, will depend heavily on the timely and successful identification, development, regulatory approval, and eventual commercialization of any such product candidates, which may never occur. To date, we have not generated revenue from sales of any products, and we may never be able to develop, obtain regulatory approval for, or commercialize a marketable product. Before we generate any revenue from product sales of any of our current or potential future product candidates, we will need to manage preclinical, clinical, and manufacturing activities, including undertaking significant clinical development, obtain regulatory approval in multiple jurisdictions, establish manufacturing supply, including commercial manufacturing supply, and build a commercial organization, which will require substantial investment and significant marketing efforts. We may never receive regulatory approval for any of our product candidates, which would prevent us from marketing, promoting, or selling any of our product candidates and generating revenue.

**Our success depends on our ability to protect our intellectual property rights and proprietary technologies, and we may not be able to protect our intellectual property rights throughout the world.**

Patent rights are generally national or regional rights. The filing, prosecution, maintenance, and defense of patent rights on our platform technologies and product candidates worldwide would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may have a different scope and strength than do those in the United States. In addition, the laws of some foreign countries, particularly certain developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our intellectual property rights in all countries outside the United States or from making, using, selling, or importing products made using our intellectual property rights in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained intellectual property rights, including patent protection, to develop their own products and may also export otherwise infringing products to territories where we have intellectual property rights, including patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products and our patent or other intellectual property rights may not be effective or adequate to prevent them from competing.

**The Company's founders, directors and executive officers own or control a majority of the Company.**

Additionally, the holdings of the Company's directors and executive officers may increase in the future upon vesting or other maturation of exercise rights under any of the options or warrants they may hold or in the future be granted or if they otherwise acquire additional interest in the Company. The interests of such persons may differ from the interests of the Company's other stockholders, including purchasers of securities in the offering. As a result, in addition to their board seats and offices, such persons will have significant influence over and control all corporate actions requiring stockholder approval, irrespective of how the Company's other stockholders, including purchasers in the offering, may vote.

**The Company may not be able to accomplish its public listing, and a market may not develop for the Shares.**

The Company is planning to become publicly listed within 12 months from the date hereof. However, there is no assurance that such public listing will ever occur or that a market will ever develop for the sale of the Shares in either event.

<u>MISCELLANEOUS</u>

<u>Entire Agreement</u>. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Agreement.

<u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on date of transmission if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

<u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

<u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. Neither party may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party.

<u>No Third-Party Beneficiaries</u>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by any other Person.

<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Florida, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this shall be commenced exclusively in the state and federal courts sitting in Volusia County, Florida.

<u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

<u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a ".pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or ".pdf" signature page is an original thereof.

<u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

**<u>WAIVER OF JURY TRIAL</u>. <u>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</u>**

IN WITNESS WHEREOF, the parties hereto have caused this Subscription Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

---

| | |
|:---|:---|
| **JABEZ BIOSCIENCES, INC.** | **JABEZ BIOSCIENCES, INC.** |
| By: | /s/ Tamara Jovonovich |
|  | Tamara Jovonovich, President and CEO |

---

**PURCHASER(S) / AUTHORIZED SIGNER**

---

| | |
|:---|:---|
| Company Name: | MedTek, LLC |
| Signature: | /s/ Jim Bullard |
| Print Name: | Jim Bullard |
|  | First Last |
| Title: | Manager |
| SSN# or FEIN: |  |
| Street Address: | 2308 W 5<sup>th</sup> Street |
| City: | Plainview, TX 79072 |
| Phone: | 806-777-1158 |
| Email: | jbullard1@aol.com |

---

**REGISTRATION TYPE:** (Select only one)

☐ Individual ☒ Company ☐ Joint Tenants ☐ Custodian IRA Account F/B/O (fill in below)

☐ Trust / Trustee: ________________________________________________Trust Date: ______________________

**IF CUSTODIAL IRA, PLEASE COMPLETE**

Authorized Signer: ____________________________________________________________________________

Registration Name: ____________________________________________________________________________

Tax ID #: ___________________________________________Phone #: ____________________________________

Address: ___________________________________________________________________________________